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ABSTRACT 
 
ALENDRONATE TREATMENT ELICITS A REDUCTION IN FATIGUE-LIFE  
OF CANINE CORTICAL BONE 
 
by 
Joseph Ryan Geissler 
 
Bone serves contradictory needs; bone must be strong yet light, and stiff yet flexible. At the tissue 
level bone material withstands cyclic loading without failing by dissipating energy via the 
formation and accumulation of microdamage. Proper removal of this damage in exchange for 
fresh tissue is vital to bone maintenance, and is achieved through a remodeling process. 
Imbalanced remodeling leads to osteoporotic fractures. Bisphosphonate drugs are proven to 
reduce fracture risk. However, the long-term effects of bisphosphonates on tissue-level properties 
are unknown. This study characterized the fatigue-life of cortical bone tissue after bisphosphonate 
treatment with alendronate (Aln). 11th ribs from 36 skeletally mature female beagles (1-2 years of 
age) treated daily with either a vehicle control (Cont, 1mL/kg saline) or Aln (0.2 or 1.0 mg/kg) 
for 3 years were evaluated. From both medial and lateral cortices, 1-6 cortical bone beams of 
uniform rectangular cross-section (0.5 x 1.5 mm) and length (10 - 12 mm) were prepared. A total 
of 90 bone beams were mechanically loaded in 4-point bending at specific stress amplitudes, 45-
85 MPa, applied sinusoidally at 2 Hz until fracture or 250,000 cycles. Compared to control, Aln 
1.0 beams exhibited significantly lower initial stiffness (15%) and cycles to failure (>3-fold, 
p<0.05). While control exhibited increased loss of stiffness as a function of increasing stress 
amplitude, this was not observed with Aln treatment. This first fatigue study of bisphosphonate-
treated bone suggests mechanisms behind the atypical cortical bone fracture patterns that have 
been observed clinically in a subset of patients on long-term bisphosphonate treatment. 
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―You can get so confused 
that you‘ll start in to race 
down long wiggled roads at a break-necking pace 
and grind on for miles across weirdish wild space, 
headed, I fear, toward a most useless place. 
 
 The Waiting Place… …for people just waiting. 
 
 Waiting for the fish to bite 
or waiting for wind to fly a kite 
or waiting around for Friday night 
or waiting, perhaps, for their Uncle Jake  
or a pot to boil, or a pair of pants or a wig 
with curls, or Another Chance.  
Everyone is just waiting. 
 NO! 
That‘s not for you! 
Somehow you‘ll escape 
All that waiting and staying.  
 
You‘ll find the bright places where Boom Band are playing 
With banner flip-flapping 
Once more you‘ll ride high! 
Ready for anything under the sky. 
Ready because you‘re that kind of guy!‖ 
  
 
 
 
-Dr. Seuss 
 
 Life if full of ups and down, peaks and valleys; success and failure meant not to 
destroy us, but to challenge our status quo. Life throws you a curve ball not to strike you 
out, but to see how you can adapt to an ever changing environment. This was most 
elegantly personified through the life a close friend who has recently passed away.  
 
As I begin my transition from masters to Ph.D., I am being presented with new, 
challenging responsibilities. One of which that I have enjoyed most is acclimating new 
students to the lab. To me, this was a chance to test my teaching abilities. However, with 
one individual, I was the student.  
 
Rohit was a young scholar full of life. He was never without a smile and can do 
attitude. Regardless of the situation, he was ready to embark on life‘s next journey no 
matter how daunting the task, never content with his current situation.  
 
The most important lesson which I have learned from my friendship with Rohit 
was that win or lose, never find yourself in a steady state; whether good news or bad, 
avoid The Waiting Place. Rohit will always remain in my thoughts and serve as the 
driving force which has not only lead me to complete the work outlined in this thesis, but 
the motivation to continue down a path of academic success. 
Lost but not forgotten. 
 
Rohit Belman 
12/18/1988 - 08/23/2011
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 1 
CHAPTER 1  
INTRODUCTION 
Bone functions to provide mechanical stability and mineral homeostasis, as well as forms 
the hard portion of the musculoskeletal system that facilitates the cyclic loading of 
locomotion, maintains body shape, and protects vital organs. Throughout growth and into 
adulthood bone tissue is constantly renewed and repaired in a process known as 
remodeling, thus maintaining structural and mechanical integrity. However, bone‘s 
metabolism and remodeling slows down with ageing and/or disease resulting in bone 
tissue loss, osteoporosis and fragile bones.  
Pharmaceutical countermeasures are often sought to reverse bone loss. 
Bisphosphonate drugs, such as alendronate, are currently the most effective treatment for 
osteoporosis and are proven to reduce fracture risk in both men and women. However, 
bisphosphonates also reduce the tissue remodeling capability of bone cells. This 
reduction may lead to local, or tissue-level, changes with serious implications for fragility 
fracture risk. In this investigation, tissue-level mechanical properties of alendronate-
treated cortical bone will be evaluated with cyclic loading.  
1.1 Bone 
At the largest scale of organization, bone is divided into two compartments, 
cortical and trabecular (Figure 1.1). Cortical bone, or the outer shell cortex, accounts for 
approximately 80% of the skeletal mass [1]. Sometimes described as compact, cortical 
bone is composed largely of osteons that are formed by concentric layers of mineralized 
2 
 
 
 
collagen fibers. Each osteon provides mechanical strength to bone, and support for nerves 
and blood vessels within a main pore known as the Haversian canal (Figure 1.1) [1]. 
Blood vessels also branch off in perpendicular directions from the vessels of the 
Haversian canal into smaller perforating, or Volkmann's canals that run within the osteon 
(Figure 1.1). This system of canals is vital to the maintenance and survival of bone tissue 
since they provide the conduit for nutrient supply. Around the Haversian canals 
concentric layers of collagen fibers form nearly perpendicular to each other. This level of 
organization adds to the strength of cortical bone and provides anisotropy that in turn 
promotes resistance against damage that may occur in the form of microcracks. 
Principally, an anisotropic material exhibits toughness due to the ability to resist crack 
extension. The engineering definition of toughness is the energy absorption capacity of a 
material. The space between the osteons also contributes to bone‘s anisotropic 
mechanical properties and is comprised of interstitial lamellae that are not part of a 
complete osteon (Figure 1.1).  
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Figure 1.1  Schematic of the cortical, trabecular, lamellar and cellular organizations 
within bone [2].   
 
Trabecular bone, also referred to as cancellous bone, accounts for the remainder 
(20%) of skeletal mass [1]. Trabeculae are described as forming a microarchitecture of 
interconnected plates and rods. They are generally found at the ends of long bones, in the 
vertebrae of the spinal column and sandwiched in-between the cortical shells of flat 
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bones, such as those of the hip and pelvis. Trabecular bone has a large surface area 
exposed to the internal environment that allows for easy exchange of ions and proteins. In 
addition, the micro-architecture of trabecular bone plays a central role in absorbing and 
dissipating the energy that is applied to bones, especially near articulating joints.  
The excellent mechanical and structural properties of bone are due to the 
regulation and organization of organic and inorganic materials by bone cells. These cells 
are osteoclasts that resorb bone, osteoblasts that form bone, and specialized osteoblasts 
known as osteocytes that play a role in maintenance of bone (Figure 1.1). Osteoblasts 
form bone by first producing an organic matrix, mainly cross linked type-I collagen 
fibers. These fibers bind hydroxyapatite Ca5(PO4)3(OH), an inorganic mineral that 
constitutes two-thirds of bone by weight [1,3]. The inorganic phase provides compressive 
strength and rigidity whereas, the organic phase accounts for flexibility, toughness and 
resistance to tensile forces [1,3,4]. The mechanical properties of bone are therefore 
largely dependent on the structural organization of these two phases by the bone cells.  
Cellular processes leave in their wake not only the hard tissue of bone but also 
many levels of porosity. The largest of these pores are the medullary canal and the 
trabecular space, both of which are filled with bone marrow, described as a nutrient 
containing tissue responsible for the formation of blood‘s cellular components, 
hematopoiesis [3]. The next smallest pores are those of the Haversian canals that contain 
the nutrient-supplying blood vessels for the deep cortical tissues. At a smaller, cellular 
level are the osteocyte lacunae, which are small pockets that house the osteocytes (Figure 
1.1). These lacunae form as osteoblasts differentiate into osteocytes and become 
embedded in their own freshly secreted matrix material. Osteocytes in these lacunae can 
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modify their local microenvironment and have recently been found capable of moving 
their cell body and long dendritic processes [5]. There are 50-100 of these dendritic 
processes per osteocyte, each residing in a canaliculus and forming the next level of 
porosity [3,6,7]. The features and abilities of the osteocyte contribute to the cell‘s ability 
to translate mechanical signals into biochemical signals and convey information through 
the dendritic processes. These processes form a communications network of connections  
with neighboring cells via gap junctions. Signals sent through this network can affect 
tissue repair [5]. 
Direct communication between cells is not limited to the osteocytes as these cells 
form junctions with cells within the marrow and those on the outside surface of bone.  
Almost this entire surface, except at articulations between bones and points of attachment 
for tendons and ligaments, is coated in a soft-tissue layer known as the periosteum [6]. 
The periosteum is connected by a bundle of collagenous perforations, known as 
Sharpey‘s fibers, and is composed of two layers (Figure 1.1). The outermost periosteal 
layer is a fibrous layer, and acts as a sheath. The inner layer is the cambium or cellular 
layer and is populated by osteoblast progenitors and chondrocytes [6]. Because this 
region is so rich in the precursors to bone forming cells, the periosteum plays a central 
role in bone growth. 
1.2 Bone Growth and Modeling 
Investigation of embryonic bone growth provides insight into the complexity of bone 
development, as well as bone repair. Two main processes are responsible for bone 
growth, intramembranous and endochondral ossification. Intramembranous ossification is 
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mostly responsible for formation of flat bones (e.g., hip and pelvis). On the other hand, 
most longitudinal growth of vertebrates occurs during formation of long bones (e.g., 
femur and humerus) by endochondral ossification in which the matrix of the initial 
cartilage anlage is systematically replaced by mineralized tissue. Initial formation of this 
anlage occurs by differentiation of mesenchymal stem cells (MSC) into chondrocytes that 
produce a cartilage matrix as they further divide. The same MSC later differentiate into 
bone-forming osteoblasts that quickly lay down a flexible and disorganized ‗woven‘ bone 
architecture (Figure 1.2) [6]. At the ends of long bones, growth occurs as chondrocytes 
divide, and secrete new collagen matrix that drives elongation [3]. 
 
Figure 1.2  Bone growth and elongation begins in the embryo and occurs until after 
puberty. Depicted in this figure, uncalcified cartilage is in light green, calcified cartilage 
in dark green, bone is black, and blood vessels are in red. The conversion of cartilage to 
bone is a gradual process facilitated by osteoclasts and osteoblasts [3,8]. 
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As bones get longer they also increase their girth by a process of ‗lamellar‘ 
osteoblast apposition known as modeling. Modeling produces the correct bone shape and 
gives strength to bone in two important ways (Figure 1.3). First, as a result of modeling, 
bones become larger. Second, the less mineralized, flexible, woven bone template is 
replaced by a more highly organized, rigid mineral lamellar bone structure. Therefore, the 
transition from woven to lamellar tissue during growth is an important process that 
establishes the mechanical properties of bone in a young adult. 
 
Figure 1.3  Diagram of the modeling occurrence during growth of proximal end of the 
tibia. Frontal section of original proximal tibia is indicated as stippled area. The situation 
after growth period of 21 days is superimposed. (A) Reduction of metaphyseal funnel 
into a narrower shaft by osteoclastic bone resorption (resorption drift) along periosteal 
surface of metaphysis (-). (B) Thickening of cortex by osteoblastic bone formation 
(formation drift) along cortical endosteal surface of metaphysis (+). (C) Enlargement of 
marrow cavity by osteoclastic resorption of metaphyseal trabecular and subendocortical 
bone (-). (D) Increase of the diameter of the shaft by periosteal bone formation first (+). 
(E) Enlargement of the marrow cavity by cortical endosteal bone resorption (-) [9]. 
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1.3 Bone Remodeling 
The most important process for maintaining the mechanical properties of bone during 
adulthood is remodeling, or the turnover of old bone tissue with new (Figure 1.4). This 
dynamic process allows for the tissue to continually renew itself with complete turnover 
occurring every 4 to 20 years in the adult human [10]. Remodeling also allows for 
alterations in bone structure in response to changes in the functional demands of the 
mechanical environment so that bone can be added where needed and removed where not 
required. Another type of targeted remodeling occurs in response to micro-damage which 
is a consequence of normal loading activity.  
 
Figure 1.4  Schematic of trabecular bone remodeling. Bone turnover describes the 
complete process of bone remodeling. This consists of an initiating event, followed by 
bone resorption, and then bone formation [11]. 
 
Targeted bone remodeling may be initiated by the death of osteocytes after an 
injury (Figure 1.5). In the case of physical damage to the cell a process of apoptosis, or 
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regulated cell death, may be initiated. During the process of dying the osteocyte and 
neighboring cells release biochemical signals that initiate the sequential and coordinated 
activity of multinucleated osteoclasts to break down bone. These osteoclasts are joined, in 
what is known as a basic multicellular unit (BMU), by mononucleated osteoblasts to 
rebuild bone (Figure 1.1) [1,3,10,12,13]. Therefore, the regulation of the BMU and the 
activity of osteoclasts and osteoblasts are vital for the survival of bone and the bone‘s 
owner. 
 
Figure 1.5  (1) Osteocytes are connected by processes to each other and to lining cells on 
the endosteal surface. (2) Damage to osteocytic processes by a microcrack produces 
osteocyte apoptosis. The distribution of apoptotic osteocytes provides information needed 
to target osteoclasts to the damage. (3) Osteoclast precursors may be delivered from the 
marrow via circulation. (4) Osteoclasts resorb damage and bone. (5) The reversal phase 
and formation of a cement line. (6) Osteoblasts deposit osteoid. (7) Some osteoblasts are 
entombed in osteoid and differentiate into osteocytes reconstructing the osteocytic 
canalicular network [14]. 
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While the remodeling process occurs similarly in all bones, differences in 
trabecular and cortical bone architecture lead to slightly different modes of action. As 
previously discussed trabecular bone has greater surface area than cortical bone and 
therefore BMU activity is surface based. In the first stage of trabecular bone remodeling, 
bone lining cells retract to expose the surface of bone (Figure 1.4) so that osteoclasts can 
gain access. The exact signaling mechanism which initiates this process is still unknown. 
However, once this signal is received and the bone lining cells retract, osteoclasts attach 
to the bone and form a ruffled border that isolates the extracellular environment from the 
hydrochloric acid that they release to disintegrate the components of bone (Figure 1.6). 
Once resorption is complete, the osteoclast detaches leaving an empty pit, known as the 
resorption pit. 
 
Figure 1.6  The mechanism of resorption activity of osteoclasts. Within the sealed site, 
acids and hydrolases are secreted to dissolve bone minerals and digest organic matrix, 
respectively [3]. Treatment with anti-resorptive agents, namely bisphosphonates, inhibits 
proper sealing between osteoclasts and bone matrix, restricting bone resorption [15]. 
 
The second stage is formation by deposition of lamellar layers of new bone matrix 
material, the osteoid, by osteoblasts of the BMU [7]. While the pit is being filled with 
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osteoid, some osteoblasts will become embedded in the freshly deposited material 
forming a communication network within the freshly mineralized tissue (Figure 1.7), 
transitioning into osteocytes, while others will undergo apoptosis after completing their 
deposition. Upon completion of osteoblastic activity, the bone lining cells cover over the 
newly formed bone. The complete bone packet is described as a hemi-osteon (Figure 
1.4). 
 
Figure 1.7  Osteoblasts that line the bone‘s surface secrete an uncalcified bone matrix, 
osteoid. Some osteoblasts will be embedded within the osteoid as this layer transitions 
into a calcified bone matrix. As this matrix begins to harden, immobilized osteoblasts 
become osteocytes and extend canals, known as canaliculi, between osteocytes [3]. 
 
As opposed to the hemi-osteon, a complete osteon results from remodeling 
activity in cortical bone. In cortical bone, osteoclasts must penetrate longitudinally 
through the layers of bone to generate a resorption cavity (Figure 1.8). The process by 
which these cells tunnel through bone is characterized as a cutting cone because of the 
shape, a cavity forms as osteoclasts break down bone. While the osteoclasts traverse 
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through bone, a capillary loop follows to supply both blood and cells to the advancing 
cone [6]. It is unclear whether the osteoclasts pull the capillary loop along or the capillary 
loop pushes the osteoclasts. Regardless, a constant blood supply is necessary for cell 
survival. Osteoblasts are recruited to the resorption cavity, and beginning from the outer 
surface of the cavity, lay down layers of osteoid forming concentric circles around the 
capillary loop. When new bone has completely surrounded the nerves and blood supply, 
the Haversian system is complete and a new osteon has been formed (Figure 1.8) [1,6]. 
 
Figure 1.8  Diagram showing a longitudinal section through a cortical remodeling unit 
with corresponding transverse sections below. (A) Multinucleated osteoclasts in 
Howship‘s lacunae advancing longitudinally from right to left and radially to enlarge a 
resorption cavity. (B) Perivascular spindle-shaped precursor cells. (C) Capillary loop 
delivering osteoclast precursors. (D) Mononuclear cells (osteoblast progenitors) lining 
reversal zone. (E) Osteoblasts apposing bone centripetally in radial closure and its 
perivascular precursor cells. (F) Flattened cells lining Haversian canal of completed 
Haversian system or osteon. Transverse section at different stages of development: (I) 
resorption cavities lined with osteoclasts; (II) completed resorption cavities lined by 
mononuclear cells, the reversal zone; (III) forming Haversian system or osteons lined 
with osteoblasts that had recently apposed three lamellae; and (IV) completed Haversian 
system or osteon with flattened bone cells lining canal. Cement line (G); osteoid 
(stippled) between osteoblast (O), and mineralized bone [1]. 
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1.4 Microdamage and Fatigue Crack Growth 
The construction of healthy bone, described in the previous section, provides a 
mechanism for energy dissipation (measured as toughness) which is vital for bones 
ability to resist fracture. To accommodate for very small changes in the stress acting 
across the surface area of bone during daily cyclic loading, minute cracks form and 
function to dissipate the load and are referred to as microcracks. Microdamage can occur 
in the form of linear microcracks or diffuse damage. Linear microcracks which arise 
under compressive loading are described as individual, well-defined cracks that 
propagate through interstitial bone. Linear microcracks are also restricted from 
propagating across osteons and are diverted around osteonal boundaries i.e. cement line 
and layers of concentric mineralized collagen fibers [17]. Diffuse damage occurs under 
tensile loading and is characterized as an array of small cracks highly concentrated in a 
single location within interstitial bone [17]. In general, microdamage is restricted to more 
densely mineralized, older bone tissue found between osteons [18]. 
During daily cyclic loading of bone, cracks that initiate and propagate throughout 
bone are confined to specific regions and prevent catastrophic failure i.e. fracture. The 
complex structure of an individual osteon described in the previous section, as well as the 
amount of osteons per unit of bone volumes, play a key role in distributing energy and 
resisting fracture [18]. A result of fatigue loading is the accumulation of microdamage at 
sites of increased mineralization. In healthy bone, damage is repaired at a rate which 
prevents coalescence. However, if damage accumulation is not repaired expeditiously, 
fracture will require less energy to initiate and propagate leading to catastrophic failure. 
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When investigating the principles of crack initiation within an engineering 
material e.g. metals, one must first recognize there are a variety of approaches, or 
mechanisms, which attempt to explain this unique event. Proposed by W.A. Wood in 
1958, crack initiation can be attributed to varying amounts of net slip across different 
planes within a metal as a result of cyclic loading [19]. As a material is fatigued, 
irreversible displacements occur along slip bands which cause the material surface to 
become rough. This surface roughening can be attributed to the formation of ‗hills‘ and 
‗valleys‘ (or extrusions and intrusions) at locations where slip bands interface with a free 
surface [19]. These slip bands, also referred to as persistent slip bands, can exist 
throughout a material and generate a preferential site for crack initiation to occur [20]. It 
has been suggested that the fatigue life a material will reduce as the materials surface 
becomes rougher. In fact, a study by Thompson, Wadsworth and Louat put forth the 
notion that fatigue life of copper can be increased by removing these ‗hills‘ and ‗valleys‘ 
by means of electrospinning the specimen‘s surface [21]. Although maintaining a smooth 
and defect free surface may increase fatigue life, it is not practical and cannot be achieved 
within bone. Therefore, crack nucleation will undoubtedly take place, resulting in crack 
propagation.  
Upon cyclic loading of bone, stress at the tips or boundaries of the cracks 
increases which facilitates crack growth and extension. Based on work conducted by 
Paris et al., fracture mechanics can be applied to fatigue crack growth in order to 
characterize its behavior. Located at a crack‘s tip is a cyclic plastic zone through which 
the crack propagates. As the crack grows, it leaves behind a plastic wake which surrounds 
the extending crack (Figure 1.9). Illustrated in Figure 1.9, if the plastic zone is contained 
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within the elastic singularity zone, then the crack growth can be characterized by Kmin 
and Kmax [22]. This relationship can also be expressed as: 
 
where da/dN is rate of crack growth, i.e. crack growth per cycle, ΔK is the stress intensity 
range (Kmax-Kmin) and R is the stress ratio (Kmin/Kmax) [22]. The integration of this 
equation provides an equation which can be used to estimate fatigue life: 
 
where N is the number of cycle required to propagate a crack, ao is the initial crack  
length, af is the final crack length [22]. 
 
Figure 1.9  Illustration of fatigue crack propagation through a material under constant 
amplitude [22].  
 
A log-log plot of da/dN versus ΔK of typical fatigue crack growth in metals helps 
illustrate the relationship between crack growth per cycle and the change in applied stress 
(Figure 1.10). This sigmoidal curve demonstrates the affects of fatigue on crack growth. 
Crack propagation is illustrated in the linear region (Region II), where crack growth rate 
is insensitive to microstructure and da/dN follows Paris Law of power: 
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where C is the fatigue crack growth coefficient and m is the fatigue crack growth 
exponent, an index of the material brittleness [22]. 
At high (Region III) and low (Region I) ΔK values, the crack growth rate tends to 
deviate from the linear region and represents crack initiation and fracture, respectively. 
Fracture toughness can be inferred from region III, as the crack growth rate increases as 
Kmax approaches Kcritical. Under high cyclic stress, the cross sectional area of the material 
will become reduced to the point where the load can no longer be sustained, resulting in 
fracture. Bone demonstrates a similar response. However, the difference in healthy living 
bone tissue versus metals is that a balance in damage accumulation and repair preserves 
strength. 
 
Figure 1.10  Log-log plot of da/dN verses ΔK demonstrating typical fatigue crack 
behavior in metals [22]. 
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1.5 Osteoporosis and Related Diseases 
Unbalanced regulation of the bone remodeling processes, bone resorption and bone 
formation, will give rise to a variety of metabolic bone diseases, including osteoporosis 
and Paget‘s disease. For example, osteoporosis may be caused either by increased bone 
resorption in which bone formation fails to keep up, or by decreased bone formation with 
little change in the rate of resorption. The result of this age-related skeletal disease is low 
bone mass and deterioration of bone microstructure (Figure 1.11). Besides the many 
different forms of osteoporosis, Paget‘s disease is a bone wasting disease in which there 
is an increase in bone loss due to over activity of osteoclasts. In an attempt to compensate 
for bone loss, bone will undergo rapid formation. However, this dramatic increase in new 
bone production leads to the formation of unorganized bone structure. For example, over 
expanded bone and increased formation of blood vessels may occur. With the latter, 
various neurological complications can arise. These changes can ultimately result in 
reduced bone strength and increased bone fragility. 
 
Figure 1.11  Depicted in this image is the microarchitecture of both an osteoporotic (left) 
and healthy (right) human lumbar. Good bone quality, visualized in healthy tissue, 
provides structural support to the bone. Poor bone quality, visualized in osteoporotic 
tissue, does not provide bone with structural support [6]. 
18 
 
 
 
Fractures due to osteoporosis are associated with great morbidity and mortality 
with 25% of hip fracture patients dying within one year of fracture occurrence. 
Furthermore, these fractures are difficult to foresee, and the fact that osteoporosis is 
generally not diagnosed until after a severe fracture demonstrates the quiet nature of this 
disease. Osteoporosis affects approximately ten million Americans, 80% of whom are 
women [23]. Annual healthcare costs due to osteoporotic fractures alone are estimated to 
increase to approximately $25 billion by 2025 [23].  The prevention of fractures due to 
osteoporosis, and other bone wasting disease, is important for medical research. 
Understanding the underlying mechanisms of osteoporotic fractures will lead to the 
development of better strategies and methods of treatment, and prevention. As such, 
methods for early detection and pharmaceutical countermeasures that would help restore 
the structural and mechanical properties of bone must be developed. 
1.6 Osteoporosis Treatments  
Apart from diet and exercise, the most common countermeasures for osteoporosis are 
drug treatments that stimulate bone formation and inhibit bone resorption. Described in 
this section are two effective interventions (Figure 1.11).  
One bone formation stimulating class of drugs is based on parathyroid hormone 
(PTH), a protein secreted into the circulatory system that functions to regulate calcium 
and phosphate levels in the body [24]. A healthy individual has about 1,135 grams of 
calcium contained in the body, of which about 99% is found in bones [24]. Proper 
regulation of these ions is vital to muscle, bone and nerve function. PTH given 
exogenously stimulates bone formation and has been found to improve several properties 
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of bone such as bone density and size, as well as bone microarchitecture (Figure 1.12) 
[25]. However, using PTH as an anabolic agent to treat osteoporosis has faced many 
challenges. Administration of PTH causes an initial stimulation of bone formation, later 
to be followed by the promotion of bone resorption [25,26]. Therefore, an optimal 
‗anabolic window‘, defined as the time period in which the activity of PTH is maximally 
anabolic, is desired for safe and effective treatment [25]. In part due to the difficulty of 
establishing this window, other methods of treatment have been favored. 
 
Figure 1.12  Biopsies from the iliac crest were collected before treatment and three years 
after. Microcomputed tomography of biopsies: (a) no treatment demonstrates thinning of 
cortical and trabecular regions and loss of overall structure. (b) Treatment with 
antiresorptive agent risedronate proves to be an effective measure, as the overall bone 
tissue structure is maintained. (c) Parathyroid hormone treatment promotes the thickening 
of cortical and trabecular regions [18,28]. 
 
Anti-resorptive agents that inhibit bone resorption, such as bisphosphonates, are 
the most commonly used treatment for osteoporosis. The general chemical formula of all 
bisphosphonates contain a nonhydrolyzable P-C-P backbone, however differences in side 
chains allows for diversity among bisphosphonates (Figure 1.13). Bonded to each 
phosphorous are double bound oxygen and two hydroxyl groups. Attached to the carbon 
are two side chains, known as R1 and R2, which account for the diversity and potency 
among bisphosphonates. Most bisphosphonates will contain a hydroxyl group at the R1 
position, making them more potent than those which lack the hydroxyl group [28]. 
a b c 
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Bisphosphonates like aldendronate and pamidronate, which contain a nitrogen atom in an 
alkyl chain, have been found to be 10-100 fold more potent than those that do not contain 
nitrogen atoms at all (etidronate and clodronate). Compounds which contain a tertiary 
nitrogen atom are even more potent, and compounds, like risedronate, containing a 
nitrogen within a heterocyclic ring are 10,000 fold more potent than etidronate [28].  
 
Figure 1.13  Bisphosphonate structures. (a) General structure of bisphosphonates [29]. 
(b) Clinically important bisphosphonates [28]. 
 
When administered, the hydroxyl group of the R1 chain and the phosphonate 
groups act as molecular hooks which allow the bisphosphonate to quickly dock to bone 
mineral surfaces. Upon resorption, osteoclasts take up bisphosphonates as they degrade 
the bone by endocytosis. The bisphosphonate becomes internalized and functions to 
disrupt signaling pathways which facilitate the normal functioning of osteoclasts to 
resorb bone. Specifically, bisphosphonates interfere with osteoclasts ability to develop a 
a 
b 
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ruffled border which normally isolates the acidic environment that breaks down bone 
[29]. This disruption will ultimately lead to apoptosis of the osteoclast, releasing the 
bisphosphonate back into bone tissue (Figure 1.14) [29].  
 
Figure 1.14  Action of bisphosphonate interrupting osteoclasts activity [29]. 
 
Bisphosphonates have been found to restore bone mineral density (BMD) and 
improve the biomechanical properties of bone [30]. Boivin et al. [2010] reported a 9.3% 
higher mean degree of mineralization of bone (MDMB) of cortical bone and a 7.4% 
higher MDMB of trabecular bone after two years of alendronate treatment.  The authors 
suggested that reduction of activation frequency and bone remodeling activity induces a 
prolonged mineralization, which increases the mineral bone density at the tissue level. 
Increased mineralization may partially explain why short-term treatments with 
bisphosphonates improve the biomechanical properties of bone, including strength (the 
load at which a material fails) and stiffness (a materials ability to resist deformation under 
an applied load prior to failure). Regardless of the mode of action, short-term treatment 
with bisphosphonates reduces osteoporotic fracture risk in both men and women.   
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Although bisphosphonates are effective at reversing osteoporotic bone loss, there 
are concerns over the long-term use of this drug and their association with atypical 
fractures [31]. These fractures have been described as atypical due to their bilateral 
occurrence, as well as their location and fracture pattern. Over the past three years, 
reports of atypical fractures of the subtrochanteric region closer to the midshaft of the 
femur have increased in patients with long term bisphosphonate regimens. These reports 
have raised concerns over the long-term safety of bisphosphonates for osteoporosis 
treatment [31,32]. Radiographs of atypical fractures show unusual cortex beaking and 
thickening of the proximal femoral shaft (Figure 1.15). 
 
Figure 1.15  It has recently been proposed that patient using antiresorptive treatment 
exhibit cortical thickening prior to atypical fracture. More commonly, fracture occurs in 
the proximal region of the femur. (a) Femoral shaft fracture in a 83 year old woman with 
9 years of treatment. (b) A similar fracture in a 77 year old woman with 5 years of 
treatment [32]. 
Beaking  
Thickening 
a b 
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Recent experimental and numerical evaluations of bisphosphonate treated bone 
tissue have shed some light on the effects of bisphosphonate on micro-damage evolution 
and fracture. In 2008, Allen et al. reported a 30% reduction in the apparent toughness of 
cortical bone after three years of treatment with alendronate in healthy canines. These 
authors attributed the reduction in toughness to changes in tissue morphology and 
architecture [33]. In a more recent study, O‘Neal et al. [2010] analyzed the effects of 
micro-damage on local mechanical stresses in the trabecular microarchitecture. These 
authors observed that a lower stress was needed to initiate fracture in the alendronate-
treated group compared to control. They concluded that alendronate changes the 
microarchitecture of the bone and reduces its ability to resist the formation of linear 
microcracks [34]. These studies suggest a possible alteration in the tissue-level properties 
of bone that may promote bone tissue fragility [34]. Regardless, no significant effort has 
been put forward in developing a thorough understanding of changes in the material 
properties, particularly fatigue-related properties of bisphosphonate-treated bone. 
Therefore, the effects of bisphosphonates on fatigue-related fragility fractures remain 
unknown. 
1.7 Objectives 
Osteoporosis is a serious public health issue and can drastically alter an individual‘s life. 
The disease which has many risk factors, some predisposed by genetics and others that 
result from life choices. A number of previous studies have demonstrated that the use of 
bisphosphonates does restore some desired structural and mechanical properties to the 
bone of osteoporotic patients [29,30]. However, there are several concerns associated 
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with long term use of bisphosphonates, particularly those associated with fatigue-life and 
bone fragility. Previous mechanical evaluations of bisphosphonate-treated bone have 
been primarily conducted with monotonic loading of whole bones. While such tests 
provide important information regarding the structural-level properties of bone, they do 
not provide data on tissue-level mechanical properties. In addition, monotonic evaluation 
does not accurately replicate the everyday loading of bone which occurs in a cyclic 
manner. Thus, the study conceived of and completed for this thesis provides an 
evaluation of the tissue-level mechanical properties of bisphosphonate-treated canine 
cortical bone tissue subjected to cyclic loading.  
Specifically, the objectives of this study were: 
1. Evaluate the fatigue-life response of control and alendronate treated cortical bone 
tissue. 
 
2. Quantify and compare any differences in stiffness as a function of stress 
amplitude for the control and drug-treated groups. 
 
3. Quantify and compare the micro-structure of cortical bone as a function of drug 
treatment and stress amplitude.  
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CHAPTER 2  
MEASURING BONE QUALITY 
Bone quality is a term used to describe bone health. Therefore, bone quality encompasses 
all aspects of bone tissue that function to provide mechanical stability and mineral 
homeostasis. This is an extensive list, partially introduced in the previous chapter. In this 
chapter and the work for this thesis, the mechanical aspect of quality will be defined as 
dependent on both structure and bone tissue material composition. At the material level, a 
balance between mineral and collagen is vital to bone tissue‘s ability to absorb energy. 
To resist fracture bone must be flexible. To resist permanent deformation bone must also 
be stiff [18]. If these competing properties are not properly in balance then normal cyclic 
loading will lead to a reduction in material properties and reduced fatigue life resulting in 
premature fracture. 
Determining an accurate way to measure bone quality can be difficult. However, 
properly assessing bone quality is vital for identifying and treating bone diseases like 
osteoporosis. Most of the literature on the subject defines bone quality based on mineral 
content. In addition to mineralization, architecture, turnover (remodeling), and damage 
accumulation are key components that have been identified to define the mechanical 
quality of bone [6]. Finally, measures of the mechanical properties of bone would provide 
the most direct assessment of bone quality. While measuring mechanical properties is not 
currently used for assessment in the clinic, laboratory methods can be applied to animal 
models for diseases and treatments, have been applied in the work for this thesis and will 
therefore be addressed in the final section of this chapter. 
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2.1 Architectural, or Structural, Properties of Bone 
There are many clinical methods, invasive and noninvasive, that can be used to 
characterize bone quality. Although highly invasive, histological processing of bone 
biopsies is the most accurate method used to investigate bone structure. With this 
technique, the excised bone tissue provides a snap shot of the current state of bone within 
a patient. From a biopsy, cross-sectional area, perimeter(s) of structures within the cross-
sectional area, distances between and number of features within an area can serve as 
primary measurements [35].  Additional primary measurements include tissue volume 
(TV) and bone volume (BV) [35]. These attributes provide a structural profile of 
individual features which can stand alone and do not require referents. Use of referents 
allows for further interpretation of the specimen. For example, bone volume fraction 
(BV/TV) is a characteristic which is indirectly measured from bone by dividing BV by 
TV. Although histological assessment of a biopsy may provide as accurate a 
representation of bone quality as currently possible, obtaining the biopsy, usually in the 
form of a 7-8 mm diameter plug (Figure 1.12) from the iliac crest is painful for the 
patient. Advances in imaging technology may provide less invasive and safe  monitoring 
of bone quality. 
2.2 Measurement of Bone Mineral 
2.2.1 Bone Mineral Density (2D) 
Noninvasive measurements of the mineralization process in bone serve as strong 
indicators of bone quality and risk of fracture. The current clinical gold standard for 
assessing fracture risk is achieved by measuring bone mineral density (BMD) through the 
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use of dual-energy x-ray absorptiometry (DEXA) [36]. DEXA measures areal bone 
mineral density (aBMD), providing a global assessment of bone‘s mineral substance due 
to x-ray attenuation by the tissues of the body. aBMD (g/cm
2
) is the amount of bone mass 
per unit area [38]. Therefore, DEXA imaging provides a two-dimensional (2D) 
representation of the mineral content within bone independent of bone size and tissue 
type [39].   
Although DEXA provides a global assessment of the mineral content in bone, its 
2D representation of bone quality may prove misleading as in the case of fluoride 
treatments that greatly enhanced both DEXA-measured BMD and fracture risk. Two 
other significant limitations of DEXA are that it does not distinguish between cortical and 
cancellous tissues, and gender and skeletal region have a large influence on the values 
reported [39].  
 
 
 
2.2.2 Mineralization of Bone  
As described previously in Chapter 1, Boivin et al. [2000] suggested that osteoporotic 
women treated with alendronate experience an increase in bone strength as a result of 
increased mean degree of mineralization of bone (MDMB) [30]. Using x-ray techniques 
similar to DEXA but carried out on bone biopsies, MDMB (grams of mineral/cm
3
 of 
bone) indicated changes in bone mineralization due to treatment. Measurements on 
biopsies from 53 postmenopausal osteoporotic women treated with alendronate for 2 or 3 
years suggested that the treatment leads to a prolonged secondary mineralization phase 
that in turn increases MDMB (Figure 2.1) [30]. The authors hypothesized that this 
increased mineralization was due to reduced activation frequency of remodeling BMUs. 
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Figure 2.1 Bell-shaped curves depicting the degree of mineralization in compact bone 
from iliac crest biopsies. Alendronate treatment shifted the curve to the right, indicating 
an increased mineralization [30].  
 
 
 
2.2.3 Bone Mineral Density (3D) 
Recent advancements in technology have brought improved methods for investigating 
bone mineral composition in three dimensions (3D) that make distinctions between 
cortical and cancellous bone tissue possible [39]. Quantitative computed tomography 
(QCT) and high-resolution peripheral quantitative computed tomography (HR-pQCT) are 
two such techniques [39]. In contrast to 2D-DEXA or conventional x-rays, CT techniques 
allow 3D recreations using computer software. This allows depth or thickness 
measurements and quantification of volumetric bone mineral density (vBMD) [35,39,40]. 
In the investigation for this thesis a similar CT technique was utilized to determine 
vBMD with even finer detail. This is known as ex vivo micro-CT. Micro-CT can be used 
on biopsies harvested from humans or animal models to measure mineralization and 
architecture at resolutions below 20 µm. In vivo lab and clinical CT have more limited 
resolution, approaching 100 µm, but allow several longitudinal time-point measurements 
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to be made on the same tissue area as adaptation to a treatment occurs over weeks to 
years. 
2.3 Turnover, or Remodeling 
Biochemical markers of bone resorption and formation serve as a minimally invasive 
technique for investigating overall bone cell activity. Markers of bone resorption include 
both plasma and urine derived markers, specifically tartrate-resistant acid phosphatases 
(TRAP) and hydroxyproline respectively. During normal bone turnover, osteoclasts 
release TRAP into circulation at a relatively constant rate. However, metabolic bone 
disorders which result in increased bone turnover exhibit elevated plasma TRAP levels.   
Hydroxyproline accounts for about 13% of the total amino acid content of mature 
collagens and about half of the body‘s collagen resides within bone [66]. Upon collagen 
degradation, molecules free hydroxyproline that are not able to be reused for the 
synthesis of new collagen. Therefore, a large majority of endogenous hydroxyproline 
present in urine can be attributed to collagen degradation from bone [66]. Changes in the 
concentration of TRAP and hydroxyproline suggest alterations in bone resorption.  
Serum derived markers, such as alkaline phosphatase (ALP), osteocalcin (OC), 
and procollagen type I propeptides (PINP), serve as biochemical markers for bone 
formation. ALP is an enzyme which plays an important role in the formation of osteoid as 
well as the mineralization process [66]. ALP activity in serum is largely attributed to 
bone formation. Synthesized by osteoblasts, OC is a small protein which binds 
hydroxyapatite [66]. Levels of serum OC associated with osteoblast activity serves as a 
biochemical marker as levels of OC correlate with bone formation rates [66]. Derived 
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from collagen type I, these peptides form both amino (N-) and carboxy (C-) terminal 
extension peptides which can be attributed to type I collagen formation. Changes in the 
presence of these biochemical markers indicate bone formation.    
2.4 Damage Accumulation 
Two possible consequences of altering remodeling activity in cortical bone are changes in 
the numbers or sizes of vascular pores of the Haversian systems, and/or changes in the 
numbers or sizes of microdamage. In either case the differences compared to normal, 
untreated bone, that may arise can be thought of in terms of damage accumulation within 
the tissue. 
 
 
 
2.4.1 Porosity 
In terms of total bone volume, human cortical porosity is about 2-3%, and cancellous 
porosity can range from 70-80% [1]. As described in the introduction, bone has a highly 
sophisticated network of blood vessels which run both longitudinally and horizontally 
throughout the mineralized structure. Maintenance of these features allow for proper 
nutrient and waste exchange. Therefore, any alterations in bone porosity can directly and 
indirectly affect the mechanical integrity of bone as a structure. Despite the known 
detrimental effects of altered porosity few studies have investigated porosity in bone 
treated with a bisphosphonate.   
A decade ago, Roschger et al. [2001] examined mineral density, mineral/collagen 
composition, and the porosity of cortical bone from iliac crest biopsies of 
postmenopausal osteoporotic women. This investigation demonstrated significant 
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increases in structural and mineralization uniformity with alendronate, compared to 
placebo control. The most compelling result was a highly significant reduction (-46%, 
Figure 2.2) in cortical porosity in the alendronate treated group [41]. The authors 
suggested that significant increases in porosity can lead to brittle bone and increased risk 
of fracture. Therefore, alendronate could contribute to the observed reduction in fractures. 
 
 
Figure 2.2  Cortical porosity measurements for placebo and alendronate treatments in 
osteoporotic women. Alendronate treatment significantly reduced porosity [41]. 
 
 
 
2.4.2 Microdamage 
The presence of microdamage within bone tissues has been well documented [42-45]. As 
previously described, microdamage is the formation of minute cracks within bone, which 
arise during daily cyclic loading as a mechanism of energy dissipation. It is generally 
accepted that, as bone ages and remodeling becomes unbalanced, damage begins to 
accumulation within bone tissue. This notion has been confirmed by Diab and Vashishth, 
who used enbloc staining to demonstrate differences in the amount and patterns of 
microdamage accumulation among old and young bone tissues. Sharply defined lines 
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were identified to be linear microcracks and areas of pooled stain were identified as 
diffuse damage [43,44].  Results from this investigation showed that older bone exhibited 
significantly more linear microcracks than young bone, while young bone exhibited 
significantly more diffuse damage than older bone tissues [45]. Additionally, this 
investigation has shown that linear microcrack formation initiates within interstitial bone 
and is either confined to this region or arrested by cement lines [45]. Similar histological 
processes have been utilized to investigate microdamage accumulation in canines treated 
with bisphosphonates [33,47,48]. 
Previous studies have demonstrated that bisphosphonate treatment results in 
increased microdamage accumulation using canine models. An investigation of bone 
turnover, microdamage accumulation and biomechanical properties of bone conducted by 
Allen et al. [2006] provides insight into the affects of bisphosphonate treatment on 
damage accumulation. Following 1 year treatment with clinical doses of risedronate or 
alendronate, these authors have shown a significant increase in damage accumulation in 
treated bone when compared to untreated bone [47]. While this investigation was not able 
to identify a correlation between microdamage accumulation and reduced mechanical 
properties, a significant non-linear correlation between damage accumulation and 
activation frequency was identified. However, comparison of individual treatments and 
microdamage yielded data which suggests that suppression of remodeling does not act as 
an accurate predictor of microdamage accumulation [47].   
To further illustrate the complications of microdamage accumulation and its 
association with reduced activation frequency and mechanical properties, Allen and Burr 
have demonstrated that the increase in damage accumulation associated with 
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bisphosphonate treatment occurs early in treatment [48]. In a similar study, 
histomorphometric analysis of canines treated with alendronate for 1 and 3 years yielded 
no significant increase in damage accumulation based on treatment duration [47]. While 
this investigation did identify higher microcrack density in 3 year treated verterbral 
trabecular bone, the accumulation of microdamage was not found to be significant. These 
authors suggest that while microdamage can be associated with turnover suppression, this 
affect is observed only early in treatment and does not progress in longer treatment 
duration [47].  
2.5 Determining the Mechanical Properties of Bone 
2.5.1 Whole Bone vs Tissue-Level Mechanical Tests: Importance of Specimen Size 
 
Conducting whole bone mechanical tests provides a ―global assessment‖ of bone‘s 
mechanical integrity [49]. Values of strength, stiffness, and the amount of energy to 
failure (toughness) can be determined, providing insight into the functional integrity of 
the skeleton. For example, Mashiba et al. [2000] suggested that short-term (12 months) 
alendronate treatment leads to alteration in the cortical microstructure of dog ribs which 
in turn alters the bone‘s mechanical integrity. While no difference was found in strength 
and stiffness, there was a significant decrease in bone toughness in the alendronate-
treated group which the authors attributed, without significant proof, to an increase in 
microdamage accumulation [51]. Although this type of whole-bone analysis provides 
useful mechanical information, the contribution of individual features within the tissue, 
including microstructure and microdamage, can only be implied. 
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While whole-bone testing considers how the bone as a complete structure 
responds to load, tissue-level mechanical testing explores bone tissue independent of the 
size and shape of the whole bone [49]. Quality and quantity of collagen fibers, as well as 
mineral density, play a central role in determining tissue-level mechanical properties such 
as elastic modulus and ultimate stress [50]. By investigating the mechanical properties of 
uniform bone beams across different treatments, changes due to the architectural make-up 
of bone can be characterized. For the investigation in this thesis, bone beams were 
excised from the cortices of canine ribs and mechanically tested in bending.  
 
 
 
2.5.2 Methods of Mechanical Testing 
 
Tension, compression, bending, torsion and shear tests serve as ways to assess 
mechanical properties (Figure 2.3). The goal of these tests is to determine the stiffness, 
load to failure and total energy absorbed prior to failure for the structure or material in 
specific loading modes. 
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Figure 2.3  Tension, compression, bending, and torsion are four ways in which a bone 
can experience load. Engineers utilize techniques that test materials under these 
conditions to investigate mechanical properties. Depending on the direction of the applied 
force, unique fracture patterns are exhibited in the cortical shaft of a long bone [52]. In 
practice, loading as shown here results in mixed modes of loading at the tissue-level. 
Shear loading is one mode present under nearly all loading conditions, is not shown here 
and is difficult to obtain as a pure mode in practice [53].  
 
In tension and compression tests the ends of the specimen are either pulled away 
from or pushed toward one another, effectively elongating or compressing the specimen, 
respectively. In general, specimens are prepared such that the majority of strain will be 
concentrated in the central portion of the specimen. Whole-bone and tissue-level 
mechanical properties have been measured in cortical bone [54]. The stresses developed 
in a sample during this type of uniaxial loading are directly related to the cross-sectional 
area of the sample.  
Since long bones are subject to large bending forces during normal function, tests 
that utilize bending forces provide useful data on mechanical properties [33,54,55]. To 
perform a bending analysis the load is applied perpendicular to the longitudinal axis, 
placing one surface in tension and the other in compression [54]. Cross-sectional 
Types of loading 
Fracture patterns 
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moments determine resistance to bending and are measured along the axes that contains 
the center of mass [56]. Bending tests are generally conducted under either three- or four-
point configurations (Figure 2.4). The three-point configuration may create high shear 
stress within the mid-span of the test beam [56]. For this investigation, the 4-point 
bending configuration was used to minimize the amount of internal shear stresses within 
the bone beams and not introduce artificial stress concentrations at the mid-span. 
 
Figure 2.4 Bending can be applied to whole bones, as well as machined beams in either 
3- or 4-point configurations [56]. 
 
Allen et al. [2008] demonstrated changes in whole-bone mechanical properties, 
namely decreased post-yield bone toughness, by subjecting whole ribs to 3-point bending 
to failure, following three years of bisphosphonate treatment. Toughness represents the 
capacity for energy to be absorbed prior to fracture. Although changes in post-yield 
toughness have not been clinically defined, it is generally accepted that a reduction 
inhibits bone‘s ability to resist fracture [56]. Interestingly, no differences were found 
between the groups for ultimate load or stiffness. The reduction in toughness (~20%) was 
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most pronounced in the higher alendronate-dosed group (Aln 1.0 mg/kg) when compared 
to control [33]. 
Torsion is applied with twist about a single axis of rotation. The polar moment of 
inertia, which represents the addition of both maximum and minimum moments in 
bending, largely determines resistance to torsion. The torsion test can provide properties 
of shear when applied to a prismatic beam of constant cross-section. Unfortunately, the 
most closely prismatic of long bones does not present a good approximation of even a 
straight cylindrical tube and torsional tests are extremely difficult to perform correctly 
[57].  
 
 
 
2.5.3 Quasi-Static versus Dynamic Loading 
 
Bone normally experiences a large range of loads and loading rates. Therefore, it is 
plausible to subject bone to one of the previously described modes of loading at different 
rates in the laboratory. The application of a steadily increasing load to a test specimen 
until fracture is known as monotonic, or quasi-static loading. Monotonic testing 
determines properties of stiffness, yield load, ultimate load, and elastic and plastic 
deformations [56]. However, monotonic testing does not represent the way in which 
bones are loaded daily in normal use. A more realistic approach to investigate bone 
properties is with cyclic, or fatigue, loading. In fatigue, cyclic loads are applied until 
failure to determine the number of cycles, or fatigue life, of the structure or material. 
During fatigue the progressive failure of a specimen is monitored. Specimens will 
fracture at stress levels much lower than those required to fracture the material under 
quasi-static loading [58]. The reason for this is that cyclic loading causes micro-
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architectural structures within the material to break down, ultimately leading to fracture  
[59]. Fatigue-life is generally characterized using a stress-life diagram, also known as an 
S-N curve. Since testing of individual specimens is to failure the generation of a S-N 
curve requires multiple specimens of uniform geometry to be tested under various stress 
amplitudes with the number of cycles to failure recorded for each [58,60]. From this 
diagram, values of fracture strength (ζf) and endurance strength (ζe) can be determined. 
Depicted in Figure 2.5 are the results of a fatigue study of both cortical and cancellous 
bone from human cadavers [60]. ζf of cortical bone and cancellous bone were 210.2 MPa 
and 134.4 MPa, respectively. ζe was 150 MPa in cortical bone and 83 MPa in cancellous 
bone. 
 
Figure 2.5  Fatigue-life diagram of cancellous and cortical bone specimens. The y-axis 
represents the stress at which bending was applied. Along the x-axis is the number of 
cycles to failure [60]. Note: cycles to failure is plotted on a logarithmic scale. 
2.6 The Relevance of Measuring Bone Quality after Drug Treatment 
Presented here are pertinent publications in which the biomechanical safety and 
efficacy of bisphosphonate drugs for dosage, treatment duration, and insertion of a ―drug 
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holiday‖ were investigated. Additional manuscripts exploring a possible association of 
bisphosphonate use with low energy atypical fractures of the femur have also been 
included. All presented studies investigated either the quality or fragility of 
bisphosphonate-treated bone. 
 
 
 
2.6.1 Bisphosphonate Treatment Restores Bone Quality in Osteoporotics 
Liberman et al. [1995] found that postmenopausal osteoporotic women receiving 
alendronate for three years had improved BMD and fracture risk profiles compared to 
placebo controls. A dose-dependent effect was noted for BMD. In this population, 
patients on placebo who had lower base-line lumbar spine BMD values demonstrated 
high incidences of new vertebral fractures over the course of the 3-year study. 
Additionally, significant loss of BMD was noted at all sites in the placebo-treated group. 
Conversely, BMD of the spine, femoral neck, trochanter, and total body significantly 
increased after 2 years with all alendronate treatment regimens [61]. While the higher 
dose group (10 mg/day) exhibited greater mean BMD than the lower dose (5 mg/day) at 
all sites, no differences in fracture risk were found due to dose. 
This study was extended to investigate long term effects [62]. Patients continued 
their regimens through three extensions (years 4-10). In general, continued 10 mg/day 
alendronate treatment was found safe, yielding mean increases in BMD of 14% in the 
spine, 5% in the femoral neck, 10% in the tronchanter, and 7% at the total proximal 
femur, compared to base-line values. Non-vertebral fractures during years 8 through 10 
were highest in a group that discontinued treatment (12%) and lowest in the 10 mg/day 
alendronate group (8%). Again, any differences due to dose were not found statistically 
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significant. The authors argued that discontinuation of alendronate treatment will cause a 
loss in bone quality. 
In a short-term study conducted by Cummings at al. [1998] referred to as the 
Fracture Intervention Trial (FIT), alendronate administration was investigated in women 
with low BMD. Patients were assigned to either placebo or 5 mg/day alendronate groups. 
After two years, the alendronate treatment was increased to 10 mg/day for two years. 
Again, alendronate treatment was deemed safe and effective at restoring BMD at all sites, 
and decreasing vertebral fracture risk by about half. After four years, placebo patients had 
lost an average of 1% BMD from their femoral neck, while alendronate-treated gained 
4%. Similarly, an average loss of 2% BMD was observed in the total hip of placebo 
patients, while alendronate treated patients exhibited a 3% increase. 
 
 
 
2.6.2 Possible Implications of Discontinuation of Treatment or “Drug Holiday”  
 
The bulk of the literature supports the view that bisphosphonates are an effective method 
to restore bone quality in osteoporotic patients. However, many doctors and patients 
believe that long-term administration can lead to adverse changes in bone quality that 
might lead to fracture. In light of this, a ―drug holiday‖ has been advocated in which 
patients receiving bisphophonates are prescribed time away from drug treatment. 
Detractors argue that discontinuation of treatment will cause a loss in bone quality. 
The most comprehensive study addressing the discontinuance of bisphosphonate 
treatment was the extension of the FIT trial, known as the FIT Long-term Extension 
(FLEX). After the first five years of treatment, alendronate was either continued or 
discontinued for the next five years [37]. Women who received alendronate at either dose 
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(5 or 10 mg/day) for the total ten-year period maintained BMD at the total hip and had 
suppressed remodeling compared to those switched to placebo. However, and most 
significantly, women who discontinued alendronate treatment showed no increase in 
fracture risk compared to those who continued treatment. Whether the fracture-risk 
benefit of taking alendronate for 5 years will persist beyond a 5 year ―holiday‖ is 
unknown.  
 
 
 
2.6.3 Atypical Fracture: A Case of Decreased Cortical Bone Quality 
Though administration of bisphosphonates has proven successful in osteoporotic patients 
at reducing the risk of fracture [36,37], recent publications have suggested that the drug 
may be linked with atypical fractures of the femur [63,64]. This is a difficult case to 
prove. There are many factors which contribute to an individual‘s risk of fracture, usually 
ahead of bisphosphonate drugs. Daily habits, like diet, smoking and exercise, can play 
key roles in one‘s bone quality. Slight differences in genetics that affect metabolic 
pathways can also account for difference in the structural and material properties of bone.  
Pre-existing disease, like diabetes, can significantly affect bone quality. There is no way 
to ensure that patients are 100% compliant with their drug regimens when 
bisphosphonates are prescribed. All these factors make for difficulty in differentiating the 
risks of bisphosphonates. 
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2.6.4 Low Energy Fractures Associated with Alendronate 
In a recently published case study, Neviaser et al. [2008] were able to identify a 
radiographic abnormal or atypical fracture pattern of the femoral shaft consistent with 
patients treated with alendronate resulting from low energy trauma. Characteristic of this 
atypical fracture was the beaking of the cortex and hypertrophied diaphyseal cortices 
around the fracture site, as well as the transverse pattern of fracture across the midshaft  
[65]. Additionally, this investigation identified the fracture occurring from minimal or no 
trauma. Of the 70 total patients identified to have had fracture resulting from low-energy 
trauma, 25 had been using alendronate [65]. The exact treatment regimen was determined 
for 16 of the 25 individuals taking alendronate. The duration of treatment for the 10 
individuals which exhibited atypical fracture was 6.9 years, while the remaining 6 
individuals who did not exhibit this fracture pattern had an average duration of 2.5 years 
[65]. More significantly, 19 of the 20 patients which were identified to have exhibited 
this atypical fracture pattern were taking alendronate [65].      
2.7 Measuring Bone Tissue Quality Under Dynamic Loading 
This thesis explores new methods for measuring bone tissue quality after drug treatment; 
fatigue analysis after bisphosphonate treatment has not previously been explored. Fatigue 
offers testing in a more ―real–life‖ mode of loading. Further, the mechanical tests 
developed allow assessment of whether a bisphosphonate‘s ability to prevent 
biomechanical property degradation at the structural level comes with any other effects at 
the tissue level. To fully understand the effects of a drug on bone quality, it is imperative 
to measure biomechanical properties at all levels of composition. 
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This work also addresses the question of how bisphosphonate treatment might 
play a role in atypical fracture. As discussed previously, treatment for up to five years 
improves BMD [47,48,33,29,30] and reduces fracture risk [37]. Bisphosphonate usage 
slows down the rate of turnover thus decreasing the rate of bone loss. However, recent 
articles demonstrate that long-term bisphosphonate use may be associated with atypical 
fracture of the femur [67,68,69]. To investigate possible mechanisms behind these 
fractures this investigation was designed to develop a novel approach for investigating 
tissue-level bone quality, particularly mechanical properties. 
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CHAPTER 3  
METHODS AND MATERIALS 
An experimental study was designed to characterize the influence of a bisphosphonate on 
the fatigue-life of cortical bone tissue. Bone tissues tested in this investigation are part of 
a collaborative effort between the labs of Drs. David B. Burr and Matthew J. Allen of the 
Indiana University School of Medicine and the group of Dr. J. Christopher Fritton at the 
New Jersey Medical School. The work encompassed in this thesis included specimen 
preparation of bone tissue beams, that were then mechanically tested, imaged with optical 
microsocopy and quantified for histomorphometrical features. Details pertaining to the  
animal model from which bone tissue beams were tested for this thesis,  are described in 
detail elsewhere [33].  Pertinent methods are presented here for a complete understanding 
of the current study.  
3.1 Animal Model 
Thirty six skeletally mature female beagles between 1 and 2 years of age were treated 
daily with an oral dosage, based on body weight, of either vehicle control (Cont, 1mL/kg 
saline) or alendronate (Aln, 0.2 mg/kg or 1.0 mg/kg; Merck, Rahway, NJ) for 3 years. 
The low dose of Aln (0.2 mg/kg) corresponds to that used for the treatment of 
postmenopausal osteoporosis, and the high dose (1.0 mg/kg) is equivalent to that used for 
treatment of Paget‘s disease. At 3 years, the dogs were sacrificed by intravenous 
administration of sodium pentobarbital (0.22 mg/kg Beuthanasia-D Special; Schering-
Plough, Union, NJ). Bones were excised, cleaned of soft tissue, wrapped in saline-soaked 
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gauze and frozen at -20ºC (Allen 2008). For the present study, the 11
th
 rib from each 
canine was obtained. All procedures and protocols were approved by the Indiana 
University School of Medicine Animal Care and Use Committee. 
3.2 Specimen Preparation 
Prior to bone sectioning, whole ribs were scanned using a microCT (Skyscan 1172, 
Belgium) along with density calibration phantoms (0.25 gm/cc and 0.75 g/cc). Scans 
were performed at an isotropic voxel resolution of 17 µm with the specimens submerged 
in a saline bath. Two ribs were scanned at a time. The images were reconstructed using 
NRecon software (V1.6.1.1, SkyScan) with compensation for misalignment. Cortical 
tissue mineral density (Ct.TMD) was measured in a 8 mm section in the mid-span.  
Canine ribs were removed from the freezer and allowed to thaw at room 
temperature for 1 hour. All cuts were made on a semi-automated Isomet 5000 (Buehler) 
precision saw (Figure 3.1). The entire rib was potted in cement (Bondo
®
, 3M) and fixed 
to an aluminum plate (Figure 3.2). The first three cuts were made to divide the rib into 
three to four approximately equal sections. Next, primary sections, 1.5 mm in thickness, 
were cut from each of the four cylindrical sections (Figure 3.3). This dimension 
represents the maximum width that could be obtained given the curvature and the 
geometry of the rib bone. Primary sections, depicted in Figure 3.4 a, were bonded to a 
plastic slide using cyanoacrylate, a rapidly polymerizing acrylic resin, fixed to an 
aluminum plate and mounted on the saw. Secondary sections, 0.5 mm in thickness, were 
then obtained from the medial and the lateral cortex resulting in beams of rectangular 
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cross-section (0.5 mm x 1.5 mm) and 10 mm length (Figure 3.4 b). The limited amount of 
cortical bone tissue allowed for 3 to 6 beams to be successfully extracted from each rib. 
 
Figure 3.1  Image here is the a) Buehler Isomet 5000 precision slicer used in this study. 
b) A close up of the precision blade used to make cuts [70].  
 
 
Figure 3.2  Depicted here is an 11
th
 beagle dog rib potted in Bondo
®
 and attached to an 
aluminum plate. This assembly was mounted on the slicer and three to four 
approximately cylindrical rib sections were obtained. Minor cuts made to the ends of ribs 
removed irregular bone geometry, depicted by dotted lines. Major cuts made to cut rib 
into cylindrical sections, depicted by dot hashed line.  
 
 
 
 
 
a 
b 
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Figure 3.3  a) Cross-section of a cylindrical section with medial and lateral cortices 
labeled.  A primary cut, 1.5 mm in length, is illustrated in red dashed lines. b) Cylindrical 
sections were again potted in Bondo
®
, attached to an aluminum plate, and mounted in the 
slicer. Marked in red is the maximum cortex in each rib section. c) Primary section cuts, 
1.5 mm in thickness, were made using the previously described methods along the red 
lines. 
 
1.5 mm a 
b c 
Medial 
Lateral 
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Figure 3.4  From each primary section, both a lateral and medial beam was cut from a 
region of maximum cortex. a) Imaged here is a primary section, 1.5 mm in thickness. b) 
Secondary bone beams were cut from primary sections, using the previously described 
method, to produce beams of rectangular cross section (0.5 mm x 1.5 mm) and 10 mm in 
length. Imaged here is the periosteal side of a beam.  
3.3 Mechanical Fatigue Testing Setup 
Beams were mounted onto a 4-point bending fixture with the periosteal side in tension 
and the endosteal side in compression. The beams were then cyclically loaded using a 
TestBench system (Electro Force, Bose) with 225 N load cell and displacement 
transducer. All tests were conducted with the specimen submerged in a saline bath 
(Figure 3.5 a). The upper (loading) fixture pins were 2 mm apart, while the lower 
(support) fixture pins were 6 mm apart (Figure 3.5 b, c). For proper alignment, the beam 
was placed in shallow groves located within the center of the lower fixture (Figure 3.5 d). 
Prior to cyclic loading, a small preload of 0.4 N was applied using the preset 
function in the Wintest Software (Version 4.1, Bose Enduratec) and the load cell was 
tared to zero. Additionally, load and displacement limits were established to prevent the 
fixtures from coming into contact with one another and potentially damaging the load 
cell. Fatigue loading was carried out under load control at a frequency of 2 Hz until, 
either the beam fractured (Nf) or the cycles reached a predefined number of 2.5X10
5
. 
Each beam was cyclically loaded at one predetermined stress value (Figure 3.6). The 
a b  
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stress amplitudes (ζa) used in this investigation ranged from 45 to 85 MPa. Loads and 
load-line displacements were recorded at 100 Hz for 0.5 sec, representing 1 cycle, at 
specific increments over the fatigue life. Cycle sampling of the collected data varied 
depending on the preselected ζa values, as well as the Nf. To best represent any changes 
in material properties, cycles were sampled at positions which represent the major 
intervals of the logarithmic scale of the plot. In all cases, the sampling was selected to 
accurately capture the loss of modulus over time.  
 
Figure 3.5  a) Bose Test Bench loading system, with saline bath to keep specimen 
hydrated. b) 4-point bending fixture with beam between grips. c) Schematic of 4-point 
bending configuration. d) Side view of lower fixture, illustrating the grooves which hold 
the sample in place (not to scale). 
 
 
 
 
 
 
 
a 
b 
c d 
50 
 
 
 
 
 
 
Figure 3.6  Preselected ζa provided maximum and minimum stress values at which a 
particular bone beam was fatigued between [71].  
 
 Stress (ζ), the measure of average force per unit area acting on a body, and strain 
(ε), the measure of deformation, were calculated using specimen geometry and sampled 
values of load and load-line displacement [59]. Using simple beam theory, values of 
applied ζ and ε were obtained using the following equations: 
 
 
where a is the distance between the inner and outer supports, L is the distance between 
the outer supports (Figure 3.5 C), b and h are the specimen thickness and height, 
respectively, P is the applied load and δ is the load-line deflection. 
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3.4 Fatigue-Life Analysis (S-N Curve) 
The fatigue-life of bone beams were characterized using stress-life diagrams (S-N 
curves). Multiple specimens of the uniform geometry previously described were 
subjected to a range of ζa values and the number of cycles to failure (Nf) were recorded. 
Beams were tested until either fracture or 250,000 cycles were reached. Once completed, 
ζa was plotted as a function of Nf to generate a S-N curve. Distribution in the S-N curve 
was modeled using the following power law:  
 
where A and B are the fatigue-life coefficient and exponent, respectively.  
 
From the S-N diagram, fatigue properties were determined, including values of 
fatigue fracture strength (ζf) and endurance strength (ζe). ζf represents the amount of ζ 
needed to propogate an existing crack or flaw and was determined by finding the y-
intercept of the S-N curve at the cycle 1 [71]. This value is also represented as the fatigue 
life coefficient (A) generated using the previously described power law. Theoretically, 
the stress below which a material will show no evidence of failure under fatigue loading 
is known as ζe [71]. Using a power fit, this value can be determined for each bone beam. 
3.5 Elastic Modulus 
Investigation of the relationship between ζ and ε provides basic material properties, as 
depicted in Figure 3.7. Forming a straight line, the region between points O and P (O 
representing the origin where no load is applied and P representing the proportionality 
limit) demonstrates that any change in stress will result in a linearly proportional change 
in strain [72]. Just beyond the proportionality limit is the elastic limit, denoted as E. This 
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value represents the maximum amount of stress that can be applied to a material in which 
no permanent deformation will occur. If subjected to ζ values above this limit, the 
material will no longer resume its original shape and size upon unloading [72]. Just 
beyond the elastic limit is the yielding point, denoted as Y, and the yield strength, 
denoted as ζy. At this point, extensive elongation, or yielding, can take place without a 
corresponding increase in load [72]. At point U, the maximum amount of ζ is applied to 
the material without causing fracture. This is known as ultimate strength (ζu) of the 
material. Representing fracture or rupture of a material, point R depicts what stress the 
material will fail under loading. 
 
 
Figure 3.7  General stress-strain curve of a material. Point O represents the origin where 
there is no initial load or deformation. Point P represents the proportionality limit. Point E 
represents the elastic limit. Point Y represents the yield point. Point U represents the 
ultimate strength of the material. Point R represents the point of rupture or fracture of the 
material [72]. 
 
As force is applied to a material, that material will tend to deform. A materials 
tendency to behave in an elastic manner, where an increase in ζ results in a linearly 
proportional increase in ε, is described as Young‘s Modulus or elastic modulus (E) and 
can be determined by investigating ζ and ε behaviors of the material. Fatigue damage can 
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be monitored by E degradation. Reported as a ratio of initial modulus or percent loss in 
modulus, the most common ways to quantify elastic modulus (Figure 3.8), are by 
measuring (1) the maximum beam deflection using linear elastic beam theory (LEBT) 
[43,73,44 ,74], (2) the unloading stiffness [75,76,77,78,79,80,81,82,83], (3) the secant 
stiffness [84, 42,77,85,86], and (4) the tangent or loading stiffness [76]. Of these four 
methods for quantifying elastic modulus or stiffness degradation, secant stiffness has 
demonstrated accuracy for bone [87] and was used for this investigation.  
 
 
Figure 3.8  This load vs. deflection graph displays two hysteresis loops from a sample 
under 4-point bending fatigue. N=1 represents the initial loading cycle and the n
th
 cycle 
represents the final loading cycle. From these hysteresis loops, mechanical measures of 
damage can be quantified in terms of elastic modulus [87]. Secant stiffness and loading 
stiffness were evaluated in this investigation.  
 
Hysteresis loops were generated at various cycles sampled along the logarithmic 
scale of cycles to failure. From each hysteresis loop generated per cycle, secant stiffness 
and loading stiffness were calculated [87]. The secant stiffness was calculated by 
determining the slope of the line which connects (ζmax, εmax) and (ζmin, εmin) for each 
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cycle (Figure 3.8). The loading stiffness was determined by a linear least square fit 
(R>0.95) to the initial loading portion of each hysteresis loop. 
3.6 Specimen Preparation for Histomorphometrical Image Analysis 
Following mechanical testing, all specimens underwent dehydration and staining for 
micro-structural analysis. Each specimen was stained with 1% basic fuchsin dissolved in 
ascending concentrations of ethanol (80%, 90%, and 100%) for 48 hours at each. 
(Appendix A). After sequential staining, samples were washed with 100% ETOH for 1 
hour to remove any excess stain. Next, each sample underwent a series of Xylene 
clearing to remove alcohol within the tissue. Finally, each sample was infiltrated using a 
series of polymethyl-methacrylate (PMMA) solutions and placed in a warm 
environmental room (~35ºC) to polymerize, thus embedding the sample within a plastic 
block (Appendix B). 
 The plastic blocks were then cut to obtain 300 m thick sections, transverse to the 
beam length (Appendix C). The sections were polished using grinding papers (Handimet 
2 Roll Grinder, Buehler) of increasing grit size, 400 to 800. Cross sections were then 
cleaned with 100% ETOH and fixed to plexiglass slides with acetylnitrile. Once fused, 
cross-section thickness was reduced to approximately 100 m using 1200 grit grinding 
paper. Next, cross sections were polished using a polishing wheel (Ecomet III, Buehler) 
with decreasing alumina slurries (average diameters of 5.0 μm, 0.3 μm and 0.05 μm) until 
a mirror finish was achieved (Appendix D). 
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3.7 Histomorphometrical Image Analysis 
Bone beam cross sections were imaged under a bright field microscope (Eclipse 50i, 
Nikon) at 10X magnification using an image capture camera (Q Imaging Go-5) and 
software (Q Capture), then stitched together using a graphics editing program (Figure 3.9 
a) (Adobe Photoshop CS5). For each bone beam, three to five cross sections from the 
mid-span were imaged and analyzed. 
Once reconstructed, cross sectional regions were analyzed for porosity, osteonal 
and inter-osteonal (also known as interstitial) space. Briefly, within Photoshop four 
image layers (perimeter, osteonal boundary, porosity with osteonal boundaries, and 
porosity without osteonal boundaries) were created and assigned separate colors (blue, 
green, yellow, and yellow respectively). Within each layer, the respective micro-
structural features were outlined using an interactive pen and tablet display (Wacom 
Cintiq 21UX) connected to a computer workstation (Dell Optiplex GX780). Each layer 
was used to quantify one of the following parameters: total bone beam area, total osteonal 
area, total porosity within osteonal boundaries and total porosity not within osteonal 
boundaries. Also reported was the number of pores per cross section. 
Quantification of these totals was achieved using an image processing program 
(NIT Image J 1.43u). Each individual layers was first imported into Image J and made 
binary (Figure 3.9 d, f, h, h, j). After establishing the desired measurements, Image J 
quantified outlined areas within the given layer. The pixel area of each layer was then 
converted into µm. This was achieved by imaging a calibrated scale marker at the same 
magnification and measuring an arbitrary length along the scale marker to determine the 
amount of pixels contained within the measured length. Primary measurements include  
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Figure 3.9  Once each cross sections is recreated, layers are added and bone parameters 
were outlined. a) Reconstructed cross section of a bone beam. b) All four layers of 
outlined features of bone displayed on bone beam. c) Blue colored outline of the 
perimeter. d) Perimeter made binary within Image J. e) Green colored outline of osteonal 
boundaries. f) Osteonal boundaries made binary. g) Yellow colored outline of porosity 
with osteonal boundaries. h) Porosity with osteonal boundaries made binary. i) Yellow 
colored outline of porosity without osteonal boundaries. j) Porosity without osteonal 
boundaries made binary.  
b. a 
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total perimeter and total osteonal area. Total porosity was found by adding the total 
porosity with osteonal boundaries and the total porosity without osteonal boundaries. 
Total interstitial area was determined by subtracting the total osteonal area from the total 
perimeter. All areal values are reported in µm
2
. 
3.8 Statistical Analysis 
To investigate variance among the data, methods of statistical analysis were employed. 
The use of non-parametric analysis of variance, specifically the Kruskal-Wallis test, was 
utilized to determine variance among data sets within each treatment with 95% 
confidence (p<0.05). To investigate variance between treatment groups, data sets were 
analyzed using one way analysis of variance (ANOVA) with 95% confidence (p<0.05). 
Post-hoc analysis was utilized to adjust for multiple comparisons in both of the 
previously described situations. Specifically, Bonferroni adjusted post-hoc analysis was 
used to correct for error which may arise when comparing multiple sets of data. 
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CHAPTER 4  
RESULTS 
The primary objective of this study was to characterize the effects of bisphosphonate 
treatment on tissue-level mechanical properties of cortical bone. Evaluations of the 
fatigue-life were conducted by applying cyclic loading to beam specimens obtained from 
11
th
 ribs of beagles. In addition, microstructural evaluation was conducted using 
conventional bone histomorphometry techniques.  
4.1 Tissue Mineral Density (TMD) 
Results from the microCT evaluation showed no significant differences in the cortical 
tissue mineral density (TMD). The TMD for control, Aln 0.2 and Aln 1.0 was found to be 
1.16±0.04 g/cc, 1.19±0.03 g/cc, and 1.15±0.06 g/cc, respectively (Figure 4. 1).  
 
Figure 4.1  Tissue mineral density values for cortical bone in the mid-span of ribs. 
Results indicate that TMD is maintained throughout the treatment with no significant 
difference among the three groups. 
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4.2 Mechanical Investigation 
The comparison of loading and unloading hysteresis loops for individual cycles during 
fatigue testing illustrates any changes in material properties as a function of cycle 
number. Degradation of stiffness was observed in all beams and is illustrated in Figure 
4.2. As the number of cycles increased, the hysteresis loops lost uniformity, eventually 
leading to a non-linear loop just prior to fracture.   
 
Figure 4.2  The gradual degradation of mechanical properties can be observed by stress-
strain data at various cycles throughout the loading period. Both a) and b) represent bone 
beams tested at a stress amplitude of 75 MPa. a) Hysteresis loops illustrating stiffness 
degradation of a control specimen. b) Hysteresis loops illustrating stiffness degradation of 
an Aln 1.0 treated specimen. 
 
Beams from the lateral cortex exhibited almost half the initial stiffness of beams 
obtained from the medial cortex (Appendix G). Analysis for porosity, as described in 
Chapter 4, showed larger average pore size in these beams with lower stiffness. 
Consequently, two criteria were used to detect possible outliers, stiffness and porosity. 
Lateral beams having an order magnitude larger pore size, and exhibiting initial stiffness 
Ei 
Ef 
Ei Ef 
a b 
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below the lower quartile of the medial beams were considered outliers (Figure 4.3) for 
the following analyses.  
 
 
Figure 4.3  Comparison of initial stiffness in medial and lateral cortices. Box plots for (a) 
control (p<0.0001), (b) Aln 0.2 (p<0.001) and (c) Aln 1.0 (p<0.0001). Beams from the 
lateral cortex exhibited lower mean stiffness than beams from the medial cortex. Note the 
dashed line at the lower quartile of initial stiffness. Any lateral beams that exhibited 
initial stiffness values below this line were considered to be outliers.  
 
 
 
4.2.1 Stiffness 
 
Initial and final stiffness values from each group are summarized in Appendix E, along 
with loss in stiffness normalized by dividing stiffness differences (Ei-Ef) by initial 
stiffness (Ei). When compared to control, Aln exhibited a reduction in stiffness with Aln 
1.0 exhibiting a significant difference in Ei vs. both control and Aln 0.2 (P <0.05) (Figure 
4.4). The average stiffness losses for control, Aln 0.2 and Aln 1.0 were 44 ± 15%, 51 ± 
13%, and 54 ± 9%, respectively. Stiffness loss as a function of stress amplitude is plotted 
b 
c 
a 
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in Figure 4.5. Stiffness loss exhibited a significant relationship with stress amplitude for 
the control group only. 
 
 
 
Figure 4.4  Comparison of initial stiffness for the three groups. * p<0.05 vs control 
unless specified.   
 
Figure 4.5  This figure demonstrates that changes in stiffness were not caused by 
changes in applied stress. 
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4.2.2 Fatigue-Life 
 
Stress-life diagrams (S-N curves) for the three groups are shown in Figure 4.6. Note that 
each data point represents one beam specimen. Beams from the Aln 1.0 group required 
lower number of cycles to failure compared to beams from the control and Aln 0.2 
groups. The power law fit to the pooled response of each group shows a dose-dependent 
reduction in fatigue-life of Aln treated cortical bone. Aln also had lower fatigue fracture 
strength (power law coefficient) with Aln 1.0 exhibiting the lowest strength (130 MPa) 
compared to Aln 0.2 (153 MPa) and control (164 MPa). 
 
Figure 4.6  S-N curves for control and Aln treated bone. 
Endurance strength (ζe) represents the stress below which a material will show no 
evidence of failure when subjected to fatigue loading. ζe for control, Aln 0.2 and Aln 1.0 
were 45, 42 and 38 MPa, respectively.  
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Table 4.1 Calculated Average Cycles to Failure for Each Group. 
 
 
ζa Cont Aln 0.2 Aln 1.0 
85 629 388 94 
75 2149 1386 366 
67 6506 4366 1243 
60 19225 13410 4104 
52 78364 57471 19322 
45 324099 250040 92447 
4.3 Structural Investigation 
4.3.1 Histomorphometry 
 
Any alterations in one area of the microstructure of bone tissue due to alendronate 
treatment might contribute to the decreased mechanical properties observed. For 
example, microdamage accumulation tends to be confined to the space between osteons, 
known as the interstitial or inter-osteonal area [45]. Total beam area is comprised mainly 
of osteonal and inter-osteonal areas, with resorptive area being a slight contributor. As 
summarized in Figure 4.7 alendronate treatment did not have a significant effect on total 
pore area, pore number or average pore size. 
Since pore area normally occupies little (<3.5%) of the total beam area in the 
beams of cortical bone that were examined, an inverse relationship exists between 
osteonal and inter-osteonal areas. As a result differences seen in one tissue area are 
reflected in the other. A large difference was observed between Aln 1.0 treated and 
control bone microstructure, with Aln 1.0 exhibiting a 20% smaller osteonal area (Figure 
4.8). 
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Figure 4.7  a) % Area of pores (normalized to beam cross-sectional area) for each group. 
b) The density or number of pores per mm
2
. c) Average pore size (μm2). No significant 
differences were found between groups.  
 
 
 
 
Figure 4.8 a) % Area of osteons (normalized to beam cross-sectional area) for each 
group. b) The density or number of osteons per mm
2
. c) Average osteon size (μm2). 
Significant differences exist between control and Aln 1.0 (p<0.05).  
 
 
 
 
a 
b 
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CHAPTER 5  
DISCUSSION 
―Cyclic fatigue tests of bone treated with BPs (bisphosphonates) have not been performed 
to determine whether the reduced toughness measured quasi-statically translates into 
reduced residual strength and shorter fatigue life of the bone under more physiologically 
relevant cyclic loading conditions. From a clinical standpoint, cyclic fatigue studies of BP 
treated bone are critical to interpreting fracture risk‖ --Allen and Burr 2011 
 
This thesis represents the first study to investigate the implications of long-term 
bisphosphonate treatment on the fatigue-life of cortical bone. In collaboration with Drs. 
Matthew Allen and David Burr, 90 cortical bone beams with uniform geometry were cut 
from the ribs of 36 skeletally mature beagles divided into 3 treatment groups. The beams 
were cyclically loaded under 4-point bending, and evaluated for both mechanical and 
structural properties. Differences in these properties between the three groups suggest 
mechanisms behind the deterioration of tissue-level properties associated with long-term 
bisphosphonate use that would lead to a determination of reduced toughness of whole 
bone as Allen and Burr referred to in the above quote. 
5.1 Mechanical Properties and Porosity 
As introduced in Chapter 1, recent publications have suggested that a side-effect of long-
term bisphosphonate use to treat low bone mass in patients may be a slight increased risk 
of low energy, atypical fractures of the femoral midshaft. Thus, many research 
investigations are underway to determine how bisphosphonate treatment alters bone 
quality and how dosing may alter these qualities.   
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If not properly removed, microdamage can provide a pathway for catastrophic 
crack propagation and material failure. This serves as an attractive mechanism to explain 
low energy fractures associated with long-term bisphosphonate use.  Clinical studies have 
demonstrated that bone quality becomes altered with age in humans [45]. It is still 
unknown whether microdamage accumulation is affected in individuals taking 
bisphosphonates and whether or not microdamage accumulation is associated with 
atypical fractures [49]. 
5.2 Mechanical Properties and Structure 
Results demonstrated that mechanical properties of cortical bone are altered after 
alendronate treatment. This was exhibited by reductions in initial stiffness and number of 
cycles to failure in alendronate-treated bone compared to control. Although an 
association between mechanical and structural properties has not been directly made, the 
results strongly suggest that bisphosphonate treatment changes the organization and 
composition of bone tissue and this can compromise mechanical integrity. 
As reviewed in the first two chapters, a major indicator of bone‘s mechanical 
integrity is stiffness. The initial stiffness of high-dose, alendronate-treated bone was 
significantly lower than control bone (~15%). This suggests that tissue-level structural 
components that normally contribute to healthy bone quality are altered by alendronate 
treatment.  
To further define alendronate‘s effects on mechanical and structural properties, 
stiffness loss was investigated as a function of stress amplitude. Control beams exhibited 
a linear relationship of stiffness loss with increasing stress amplitude, i.e. as expected 
67 
 
 
bone has greater stiffness loss at higher loads. Conversely, alendronate treated bone 
exhibited an extremely weak relationship between stiffness loss and stress amplitude. 
This occurred regardless of dose and indicates that long-term bisphosphonate treatment 
impairs bone quality. To investigate possible mechanisms behind these mechanical 
differences, structural properties of cortical bone were investigated. 
In general, the composition and organization of structural components contribute 
to bone‘s strength and stiffness, or ability to withstand load. As introduced in Chapter 1, 
cortical bone tissue is populated with Haversian systems including canals and osteocyte 
lacunae; each structure performs a specific and vital function while also contributing to 
the overall porosity of cortical tissue. As reviewed in the first two chapters, 
bisphosphonate treatment could lead to increased tissue uniformity and reduced porosity. 
Therefore, these two characteristics may offer insight into the observed reduction in 
fatigue-related, material properties of bisphosphonate treated bone. Roschger et al. 
[2001] demonstrated a 46% reduced cortical porosity in alendronate-treated iliac crest 
bone from postmenopausal osteoporotic women compared to non-osteoporotic women. 
Additionally, they found that alendronate treatment increased mineralization uniformity. 
While this parameter was not explicitly investigated in this study, increased 
mineralization uniformity could be a consequence of reduced remodeling in conjunction 
with a prolonged secondary mineralization phase within older interstitial bone. The 
amount of this type of cortical bone was found increased in the alendronate-treated bone 
examined for this thesis.   
Somewhat surprisingly, differences in porosity were not found; all groups 
exhibited similar porosity in line with normal porosity for rib bone of skeletally mature 
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female beagles. Porosity is largely determined by the number and size of Haversian 
canals. Neither was found to be affected. The contribution of lacunae was not directly 
investigated in this study. However, microCT measured BMD, which is largely affected 
by both Haversian canals and lacunae, was not found different between the 3 groups. The 
largest effect of alendronate treatment appeared to be on the compositional proportion of 
osteonal to interstitial cortical bone.  
Combined, the results of this investigation suggest that tissue-level structural 
components normally contributing to healthy bone‘s stiffness are altered by alendronate 
treatment and contribute to reduced stiffness. These structural effects may also alter the 
way in which stiffness declines over time during cyclic loading. While numbers of 
osteons were not affected by treatment, the average size of each osteon was reduced, 
indicating that activation of remodeling BMUs was not affected by alendronate but the 
BMU size was made smaller. This is not unexpected given that bisphosphonate use has 
been shown to reduce the amount of bone resorbed by each osteoclast as was pointed out 
in Chapter 1. Another consequence of a smaller average osteon size was an increase in 
interstitial space. The interstitial area represents bone that is older when compared to 
osteonal bone. As interstitial area increases, the anisotropy of cortical bone is also 
reduced. 
5.3 Fatigue-life 
As pointed out in Chapter 1, an anisotropic material exhibits toughness due to an ability 
to resist crack initiation and extension. These toughening mechanisms improve a 
material‘s ability to withstand cyclic loading and depend on the capacity for energy 
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dissipation. The formation of microdamage, in the form of linear cracks and diffuse 
damage in bone serves as one mechanism by which energy is dissipated. In healthy bone, 
this damage is resorbed and replaced at a steady rate by remodeling. However, as bone 
ages, removal occurs at reduced rates. Furthermore, aged tissue demonstrates different 
microdamage accumulation patterns [45]. Older bone accumulates more linear 
microcracks compared to younger bone which accumulates more diffuse damage [45]. 
This suggests that as bone tissue ages, increased microdamage accumulates that may 
contribute to the progressive deterioration of bone quality and mechanical properties.  
Previous studies completed with quasi-static loading of whole ribs from the same 
beagles examined for this thesis demonstrated a decreased toughness (~20%) after 1 year 
of high-dose alendronate treatment [33,51]. The study for this thesis represents the first 
fatigue evaluation of bisphosphonate-treated bone, and only the second time that 
bisphosphonate-treated bone tissue has been mechanically tested after machining beams 
of consistent geometry. Aln 1.0 treated bone required 5-fold or even fewer cycles to 
failure compared to the other groups. Taken together with an approximate 20% reduction 
in fatigue strength these results imply that high-dose alendronate treatment directly alters 
bone‘s ability to withstand cyclic loading, and could result in premature fracture.   
 Although this study did not include microdamage analysis, recent publications 
have investigated microdamage accumulation in canine ribs following 1 and 3 years of 
bisphosphonate treatment [47,33,51].  Mashiba et al. [2007] concluded that 1 year of high 
dose alendronate treatment resulted in significant damage accumulation five to seven fold 
greater than control. Similarities between that study and this investigation suggest that 
microdamage accumulation in alendronate treated bone may be associated with the 
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reduction in fatigue-life observed. However, studies conducted by Allen et al. [2008] 
demonstrate no significant difference in damage accumulation within beagle ribs between 
1 and 3 years of alendronate treatment. Because there was a significant 20% reduction in 
toughness for 3-year treated whole ribs only, the authors concluded that the reduction in 
mechanical properties of alendronate-treated bone was not significantly attributed to 
damage accumulation. This current study was not designed to examine differences in 
treatment duration or damage accumulation and therefore, the contribution of treatment 
duration or damage levels on cycles to failure observed in alendronate-treated bone are 
only be speculative.  
During healthy remodeling of cortical tissue, old or damaged osteons are replaced 
with new osteons of similar shape and size, maintaining the overall osteonal area (Figure 
5.1). The conservation of osteon size not only maintains the amount of interosteonal area 
where damage can accumulate, but also ensures that osteons remain in close proximity to 
one another providing structural reinforcement.   
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Figure 5.1  Healthy cortical remodeling results in the production of Haversian canals 
(osteons) similar in shape and size across generations [2].  
 
However, this study has demonstrated that high dose alendronate treatment results 
in a 17% reduction in osteonal area, while conserving the total number of osteons. This 
indicates that with high dose alendronate treatment, the overall size of individual osteons 
is significantly decreased in cortical tissue as a function of time (Figure 5.2). This 
reduction in osteon size has two implications: 1) lack of osteon reinforcement, and 2) an 
increase in the space between osteons (i.e. interosteonal area). Due to the shrinking of 
osteons over time, these structures can no longer reinforce one another as observed in 
healthy remodeling. Additionally, an increase in interosteonal area suggests that there is 
more area for damage to accumulate between osteons (Figure 5.3). Previous research has 
demonstrated a five to seven fold increase in damage accumulation within cortical bone 
Interosteonal Area 
TIME 
72 
 
 
treated with high dose alendronate [51]. Therefore, it can be suggested that an increase in 
interosteonal area may lead to in an increase in damage accumulation, resulting in the 
reduction of tissue-level mechanical properties of cortical bone.  
 
 
 
 
 
Figure 5.2  The gradual reduction in osteon size over time is illustrated here. Yellow dots 
represent Haversian pores. 
 
TIME 
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Figure 5.3  This cartoon illustrates the increase in interosteonal area observed in long-
term alendronate treated tissue, which suggests an increase in area for damage to 
accumulate when compared to healthy tissue.  
5.4 Limitations 
Limitations to this investigation exist in both the animal model, and preparation and 
testing of bone tissues from the animal model utilized. Ideally, the effects of drugs on 
human tissues are best studied in tissues from patients and appropriate controls. However, 
such a controlled study as conducted for this thesis would not be possible in a patient 
population where taking biopsy specimens large enough for mechanical testing is painful 
and collecting a large enough sample size is not feasible in a 2-year study time frame. 
Canine bone tissue exhibits remodeling similarities to that in human bone that allow for 
its use in determining the effects of drugs on bone tissue. Many other animals, including 
rodents, do not exhibit bone remodeling and could not serve as models for human bone 
conditions. 
Healthy Tissue Aln Treated Tissue 
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Limitations concerning the beagle dog model are described in detail elsewhere 
[90]. In summary, canines were not estrogen-deficient and did not exhibit low bone mass 
prior to treatment. The goal of this study was to investigate the effects of alendronate 
treatment on normally remodeling bone. Now that this thesis has determined the fatigue 
effects of alendronate on normal bone further work should investigate these effects in 
osteoporotic conditions which normally warrant bisphosphonate treatment. 
This study was limited to one duration of alendronate treatment. Three years of 
treatment in this model is considered to be long-term, equivalent to at least 5 years of use 
in humans due to the higher metabolism of dogs. While likely that the duration of 
treatment would affect outcomes, conclusions regarding the duration of treatment cannot 
be made. For example, whether the one year of treatment that has been associated with an 
increased accumulation of microdamage in the beagle rib would show similar fatigue 
loading effects to the 3-year results found in the current study is unknown. The dose of 
alendronate administered was found to affect fatigue life and other mechanical properties 
differently; the effects on initial strength, and fatigue life and strength appeared to be 
proportional to dose administered. The high dose administered in this study was chosen 
to be equivalent to that given clinically for Paget‘s disease as reviewed in Chapter 1. The 
low dose was chosen to be equivalent to that given for treating osteoporosis. 
A final limitation of this study regarding the model was that only one bone from 
the beagle was examined. The choice of rib bone versus another load-bearing bone was 
made to capture any effects of alendronate on remodeling. Canine ribs (and those in 
humans) undergo significant remodeling compared to other bones due to the relatively 
high frequency of loading associated with breathing. However, further investigations of 
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the mechanisms behind cyclic loading and atypical fractures should take into account 
differences that exist in cortical bone at different anatomical locations.   
No previous studies have investigated the fatigue-life or tissue-level properties of 
bisphosphonate-treated rib bone. Several limitations regarding the preparation and testing 
of bone tissues were confronted in this investigation, some foreseen and some not. Rib 
cortices were thin enough to present significant machining challenges. Each individual 
rib was visually surveyed to identify thicker cortical regions for both primary and 
secondary cuts. However, human error occurred during cutting and three ribs produced 
no purely cortical beams. This difficulty in machining beams was foreseen and whole-rib 
microCT data was collected prior to beam fabrication in an attempt to identify thicker 
regions of bone to target for beam excision. In theory, this prior mapping should aid the 
machining process and further work should be devoted to improving the yield of bone 
beams from thin cortices. 
Other limitations pertained to the mechanical loading setup. The longest fatigue 
loading on beams tested under low stress amplitudes sometimes resulted in beams 
becoming wedged between the lower loading pins. Investigation of these beams 
determined that the edges of the loading pins began to chew away material as the beam 
reached higher cycles of loading. In these cases, the initial decrease in elastic modulus 
was followed by an unexpected increase in modulus. To avoid this possibly confounding 
interpretation, the experiment was designed to allow beams a maximum of 250,000 
loading cycles. Establishing such a cycle limit has been used in previous fatigue-loading 
studies. It is unlikely that this limit significantly affected the determination of fatigue life 
relationships.   
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5.5 Major Results 
Direct links between long-term bisphosphonate use and atypical fracture are difficult to 
establish. This study does suggest that bisphosphonate induced remodeling suppression 
directly alters tissue-level cortical properties and can compromise the overall integrity of 
canine rib bone tissue subjected to fatigue loading.  
Bisphosphonate treatment was found to significantly decrease the initial stiffness 
of cortical bone beams compared to controls. Additionally, the relationship of stiffness 
loss with the amplitude of loading observed in control beams was not observed in 
alendronate-treated bone, suggesting a smaller dependence on energy to fracture in 
treated versus healthy canine cortical bone tissue.  
 Of greatest importance, this investigation examined the effects of cyclic loading 
on bisphosphonate-treated cortical bone for the first time and found significant effects on 
reducing fatigue life by > 3-fold or greater. While others have reported mechanical 
properties of bisphosphonate treated bone using quasi-static and whole bone testing to 
demonstrate a global assessment of bone, this study has utilized methods of testing at the 
bone-tissue level.   
5.6 Further Work 
Considering that bisphosphonates suppress remodeling and that microdamage is 
generally confined to older, highly mineralized regions of bone tissue, a plausible 
explanation for the observed reduction in cycles to failure exhibited by alendronate-
treated bone may be due to excessive damage accumulation. In principle, cracks would 
propagate more easily through a material with voids or damage compared to a solid. 
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Therefore, it can be suggested that extensive damage accumulation from suppressed 
remodeling would require fewer cycles to failure. Quantifying damage within the 
unloaded portions of the beams would constitute an important addition to the study for 
this thesis. 
Although fatigue analysis of bone simulates real world conditions of cyclic bone 
loading, quasi-static and creep testing also provide mechanical information vital to the 
overall assessment of bone tissue. To further develop and strengthen this investigation, 
creep loading of bone beams excised from ribs of the same animals should be conducted. 
This would provide an even more comprehensive analysis of the mechanical properties 
affected by alendronate treatment. Eventually, such studies as this one will bring to full 
light the mechanisms behind the affects that reduced remodeling has on bone tissue 
quality and lead to improved long-term treatment for osteoporosis and other bone disease.  
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CHAPTER 6  
CONCLUSIONS 
As the first study to investigate changes in tissue-level fatigue-life of bisphosphonate 
treated cortical bone, results from this study offer insight into the possible link between 
long-term treatment and atypical fractures of the femur. While this investigation showed 
that high and low dose alendronate successfully maintained cortical tissue mineral 
density, results also demonstrate that alendronate treatments reduce the tissue-level 
mechanical properties of cortical bone under fatigue loading. High dose alendronate 
treated cortical bone exhibited a significant 21% reduction in initial stiffness when 
compared to control.  High dose alendronate treatment also resulted in a 5-fold reduction 
in the number of cycles to failure, indicating that high dose alendronate treated bone will 
fracture with 5 times fewer cycles when compared to control. Additionally, the high dose 
alendronate treatment exhibited a significant reduction in osteonal area (-17%). This 17% 
reduction in osteonal area indicates a 17% increase of interosteonal area.   
 This study has demonstrated that long-term treatment of alendronate does alter 
cortical bone micro-structure. As a result of altered micro-structure, the overall 
mechanical integrity of alendronate treated cortical bone becomes compromised resulting 
in the reduction of mechanical properties, specifically the significant reduction in the 
amount of cycles required to fracture cortical bone beams. This reduction in cycles to 
failure offers a possible mechanism by which low energy, atypical fractures may be 
associated with long-term bisphosphonate treatment.  
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APPENDIX A 
BASIC FUCHSIN STAINING PROTOCOL 
Basic stain for calcified bone specimens  
 
ALL STEPS OF PROTOCOL ARE TO BE CONDUCTED IN OR NEAR SINK 
****Gloves, safety goggles, and lab coat or apron for all steps of protocol**** 
 
Basic Fuchsin (Pararosaniline Chloride) 99%, pure---Acros Organics 
C.I.: #42500               CAS: 569-61-9             Molecular weight 323.83 
 
:::CAUTION::: 
This stain is toxic and is a suspected carcinogen. ALWAYS wear gloves, safety goggles, 
and lab coat or apron while working with this stain. Avoid contact with skin. All work 
should be done in or near a sink. 
 
Solutions: 
1% BASIC FUCHSIN STOCK 
 Basic Fuchsin Powder    1.0 gram 
 100% Ethanol      100.0 ml 
**Let 1% stock solution mix for 48 hours prior to dilution** 
 
80% BASIC FUCHSIN 
 1% Basic Fuchsin Stock    8.0 ml 
 Distilled Water     2.0 ml 
 
90% BASIC FUCHSIN 
1% Basic Fuchsin Stock    9.0 ml 
 Distilled Water     1.0 ml 
 
100% BASIC FUCHSIN 
 1% Basic Fuchsin Stock    10.0 ml 
 
 
Procedure:    Duration 
1) 80% Basic Fuchsin   48 hours on magnetic stir plate 
2) 90% Basic Fuchsin   48 hours on magnetic stir plate 
3) 100% Basic Fuchsin   48 hours on magnetic stir plate 
 
***Continue with embedding protocol for ETOH washing, Xylene clearing, 
 and PMMA infiltration***
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APPENDIX B 
EMBEDDING PROTOCOL 
Polymethyl methacrylate embedding for calcified bone specimens 
 
**To be conducted after Basic Fuchsin staining protocol** 
ALL STEPS OF PROTOCOL ARE TO BE CONDUCTED UNDER HOOD 
***Gloves, safety goggles, and lab coat or apron for each step in protocol*** 
 Xylene CAS: 1330-20-7  
 PMMA CAS: 9011-14-7 
 
Procedure:    Duration 
1) ETOH WASH 
 Fresh 100% ETOH  10 minutes 
 Fresh 100% ETOH  1 hours (additional washings if excess dye) 
 
2) CLEARING 
  
 Xylene I   3 hours on shaker 
 Xylene II   24 hours on shaker (overnight) 
 Xylene III   3 hours on shaker 
 
3) INFILTRATION 
 Hard PMMA I   24 hours on shaker (room temperature overnight)  
 Hard PMMA II  24 hours (refrigerator overnight) 
 Hard PMMA III  24 hours (refrigerator overnight) 
  
After successful infiltration, bone specimens are placed into a small jar with a thin layer 
of hardened PMMA. Additional liquid PMMA III is added to submerge the specimen, 
and left to settle for 2-3 days. Jars can then be placed in a hotroom (~40ºC) until 
completely hardened. To free hardened PMMA with embedded sample, place jar in thick 
plastic bag and hit with hammer until glass jar breaks. Carefully pour glass shards into 
glass receptacle and remove plastic block. Rinse block with water to remove small glass 
pieces. Gently grind both surfaces to remove any remaining glass and make surfaces 
parallel.   
 
PMMA II contains:    100 ml PMMA I and 1 gram Benzoyl Peroxide 
PMMA III contains:    100 ml PMMA I and 2.5 grams Benzoyl Peroxide 
 
***Continue with slicing protocol***
 81 
APPENDIX C 
SECTIONING PROTOCOL 
Block sectioning of embedded calcified bone specimen 
**To be conducted after PMMA embedding protocol** 
PRIOR TO CONDUCTING THIS PROTOCOL, review Buhler Isomet 500  
Precision Saw hand book for detailed operating instructions 
 
Note: Vice mounting on micrometer can be moved along the x-axis. Left and right 
directional buttons located on the front display allow for –X and +X movement, 
respectively. Blade mounting can be moved along the y-axis. Up and down directional 
buttons located on the front display allow for –Y and +Y movement, respectively. 
Additionally, hand crank locate on the front panel allows for more efficient movement 
along the y-axis. 
 
Block Specimen Preparation: 
1. Label the wall of each block with the bone beam number_letter with a 
Shapry. 
2. To track the upper left corner of all sections to be cut, color half of the top 
face of the block with a Sharpy parallel to the length of the bone beam. 
3. Using a caliper, measure the thickness of the block and write this value on 
the block using a Sharpy.  
4. Using glue, fix the block to a plastic slide. 
5. Next, fix the plastic slide/block assembly to an aluminum plate using glue 
and mount the plate in the vice within the saw. 
Precision Sectioning Protocol: **Review user hand book before operating saw** 
1. Turn on Buheler Isomet linear precision saw.  
2. Hard home the system. 
i. Using the hand crack on the front of the slicer, slowly glide the 
blade (to the right) towards the back of the unit until the display 
reads ―WARNING ARM LIMIT‖ 
ii. Then, glide the blade (to the left) towards the front, stopping just as 
the warning disappears.    
3. Using the hand crank, slowly glide the blade along the y-axis towards the 
specimen. Rotate crank left. 
4. Using the left and/or right directional buttons, advance the specimen along 
the x-axis to aligning the blade with the location of the initial cut.   
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5. Once the blade is properly aligned, slowly glide the blade close to the face 
of the block and note the distance. Rotate crank left. 
6. Glide blade 4 mm away from the block. Rotate crank right.  
7. Zero the system by pushing the zero button. The distance remaining 
should then read 0 mm. 
8. Input the desired cutting parameters 
i. Blade Speed     
ii. Feed Rate 
iii. Cutting Length 
iv. Sample thickness 
v. Specimen Quantity 
vi. Blade Thickness 
 
9. Ensure cutting liquid is directed over specimen. 
10. Recheck cutting parameters, as well as specimen alignment. 
11. To begin sectioning, push Start Cycle. 
12. To pause sectioning, wait until blade has returned to its point of origin and 
the micrometer has advanced the specimen, then push Pause Cut. To 
restart, put Start Cycle. 
13. Once the entire specimen is sectioned, remove the aluminum plate from 
the saw. 
14. Remove the block from the plastic slide and rinse the block with water and 
dry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***Continue with mounting protocol for disassembling of block and 
 mounting of sections onto slides*** 
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APPENDIX D 
MOUNTING PROTOCOL 
Section mounting for calcified bone specimens  
**To be conducted after PMMA embedding protocol** 
PROTOCOL MUST BE CONDUCTED UNDER VENTILATION 
 
Acetonitrile::   CAS Number: 75-05-8 
  Chemical Formula: CH3CN 
  Molecular Weight: 41.05 g mol
-1
  
 
Caution: Acetonitrile is flammable and can cause irritation to the eyes. One 
should be in a well-ventilated area when handling acetonitrile.  
 
Specimen Preparation 
1. To prepare the specimen for mounting, first remove each section one by one from 
the block. Place the same face down with each section.  
2. Dry each section and number each section using a pen or marker.  
3. Using a scissor, remove the upper left corner of each section. 
4. Using grinding papers under water irrigation grind the bottom surface of each 
section. 
5. Next, use a polishing wheel and decreasing alumina diameter slurries to polish 
each section to a mirror finish.  
6. Finally, to remove microscopic debris, place the sections in a beaker containing 
deionized water into a sonicating water bath for about two minutes. 
7. Dry off sections and prepare them for mounting.  
Specimen Mounting 
1. Set Up 
a. Small beaker with 100% ETOH with dropper. 
b. Dropper filled with Acetonitrile. TO BE USED UNDER GOOD 
VENTILATION. 
c. To prepare the plastic slides, remove the paper covering from one side and 
write the beam number_letter and slice number on opposite side. Prepare a 
slide for each sample. 
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2. Section Mounting 
a. Using forceps and a dropper, clean the exposed surface of slides pertaining 
to one beam using 100% ETOH. 
b. Allow all slides to be completely dry before advancing to the next setp.  
c. Using forceps and a dropper, clean both surfaces of one segment with 
100% ETOH.  
d. Next, apply one to two drops of acetonitrile to the sterile surface of the 
slide. 
e. Apply the sterile cross section to the slide utilizing capillary forces by 
drawing the acetonitrile across the section, reducing the formation of 
bubbles.  
f. Immediately, apply pressure across the cross section.  
--Apply the thumb roll for 15 sections. Also can use a water filled    
tube as a rolling pin to evenly apply pressure across the section.  
g. Next, apply perpendicular pressure with thumb for 30 sections. 
h. Once all sections from one beam have been mounted, stack slides on top 
of one another, placing a piece of parafilm between the samples. 
i. Apply a clamp and allow adequate time for plastics to properly fuse.  
j. Repeat these steps with remaining beam section.  
 
3. Thickness Reduction :: 300 microns to ~100 microns 
a. Once section and slide are fused, measure the thickness of the slide using a 
caliper and write this value on the back of the slide.  
b. Using 600 grit grinding paper under water irrigation, reduce the thickness 
of the cross section. Monitor progress by measuring the thickness of the 
specimen and slide periodically. 
c. Once target specimen thickness is achieved,  polish section using 
decreasing alumina diameter slurries until mirror finish. 
d. Place slides in sonicating water bath for two minutes to remove 
microscopic debris.  
 
4. Labeling 
a. Wipe both surfaces with a kim wipe to remove any surface debris.  
b. Write the beam number_letter and slice number on white labels and apply 
them to the slides. 
c. Place slides in slide box. 
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APPENDIX E 
DATA FOR ALL THREE GROUPS 
The following tables contain the data from this investigation for all three groups. Yellow 
boxes indicate beams which came from the medial position and green boxes indicate 
beams that came from the lateral position. 
 
Table E1. Control Data 
Beam 
Number 
Stress 
(MPa) 
Nf 
(Cycles) 
Secant Ei 
(GPa) 
Secant Ef 
(GPa) 
Secant Loss 
(GPa) 
Secant 
Loss 
(%) 
59315_B 45 125000 10.77 9.44 1.33 12.34 
59234_A 45 100000 9.42 6.13 3.29 34.96 
60644_B 45 250000 11.09 
   59315_D 52 250000 11.54 7.79 3.75 32.48 
60667_A 52 250000 13.39 11.12 2.27 16.93 
60628_F 52 40000 12.34 6.76 5.58 45.24 
60632_B 60 15319 10.60 3.03 7.57 71.43 
59234_C 60 5405 8.87 5.52 3.35 37.82 
59677_C 60 14731 10.34 5.25 5.09 49.25 
60632_D 67 12564 10.39 5.59 4.80 46.22 
60628_D 67 6260 10.40 4.48 5.91 56.88 
60707_B 67 9067 12.39 6.16 6.22 50.24 
60632_F 75 4916 11.28 6.08 5.20 46.07 
59257_D 75 2053 11.33 5.40 5.93 52.31 
60628_B 85 382 9.65 4.99 4.66 48.29 
60644_H 85 806 10.43 5.25 5.18 49.64 
60628_E 85 1756 13.09 5.89 7.19 54.95 
Average 
  
11.02 6.18 4.83 44.07 
STDEV 
  
1.24 1.92 1.69 14.66 
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Table E2. Aln 0.2 Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beam 
Number 
Stress 
(MPa) 
Nf 
(Cycles) 
Secant Ei 
(GPa) 
Secant Ef 
(GPa) 
Secant Loss 
(GPa) 
Secant 
Loss 
(%) 
60636_F 45 226880 10.62 4.84 5.77 54.38 
59256_F 45 205000 10.01 6.95 3.06 30.58 
59258_E 45 180000 11.21 6.23 4.98 44.43 
60636_A 50 97986 11.26 4.91 6.34 56.35 
60592_B 52 31000 9.47 5.25 4.22 44.59 
60592_F 52 7705 8.05 5.09 2.96 36.77 
60636_E 52 49173 10.08 4.70 5.38 53.36 
59258_D 55 53804 10.45 6.64 3.81 36.43 
59258_B 60 11000 11.90 3.87 8.03 67.48 
60592_D 60 21825 11.10 5.33 5.77 52.00 
60636_C 60 13936 9.91 5.72 4.19 42.30 
60631_G 60 600 8.77 5.43 3.34 38.08 
60631_D 67 19000 12.62 6.88 5.74 45.49 
60631_H 67 6250 12.28 5.13 7.15 58.24 
59256_A 67 1696 8.68 2.62 6.06 69.81 
59256_G 67 3561 8.89 2.42 6.47 72.79 
59219_F 75 3282 10.75 6.20 4.55 42.31 
60631_F 75 1956 12.38 5.64 6.75 54.50 
59256_C 75 550 8.84 5.68 3.16 35.75 
59219_B 85 485 8.68 4.47 4.21 48.54 
60631_B 85 604 9.64 2.84 6.80 70.51 
60642_E 85 1250 11.93 6.71 5.22 43.74 
60631_E 85 273 8.68 2.74 5.94 68.40 
Average 
  
10.27 5.06 5.21 50.73 
STDEV 
  
1.39 1.37 1.42 12.52 
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Table E.3 Aln 1.0 Data 
Beam 
Number 
Stress 
(MPa) 
Nf 
(Cycles) 
Secant Ei 
(GPa) 
Secant Ef 
(GPa) 
Secant Loss 
(GPa) 
Secant Loss 
(%) 
59211_D 45 60000 10.58 10.58 - - 
60641_C 45 45000 7.91 4.94 2.97 37.51 
60593_A 45 98689 7.57 3.03 4.55 60.06 
59238_A 45 40555 8.35 4.64 3.71 44.44 
59231_A 52 18204 8.88 4.03 4.86 54.68 
60641_B 52 26135 10.07 4.40 5.67 56.33 
59238_B 52 84406 10.93 6.30 4.63 42.37 
60750_E 52 10500 8.74 4.08 4.65 53.25 
59231_D 60 4550 10.20 5.85 4.35 42.64 
59236_D 60 953 8.58 4.03 4.55 53.04 
59211_A 60 1591 8.21 2.74 5.47 66.63 
60809_A 60 2881 7.76 3.60 4.16 53.64 
59231_C 67 2930 9.57 4.53 5.04 52.70 
59211_B 67 3206 9.38 4.62 4.76 50.75 
60643_A 67 466 8.22 2.42 5.80 70.58 
60657_D 67 1007 7.35 3.97 3.38 45.99 
60750_D 75 218 7.33 3.86 3.47 47.31 
60643_C 75 425 8.55 3.53 5.02 58.71 
60643_D 75 1662 10.10 3.19 6.92 68.46 
60593_B 85 321 7.57 3.03 4.55 60.06 
59231_E 85 152 8.06 2.92 5.13 63.71 
Average 
  
8.76 4.30 4.68 54.14 
STDEV 
  
1.11 1.74 0.91 9.15 
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APPENDIX F 
OUTLIER DATA FOR ALL THREE GROUPS 
The following tables contain the data of outlier beams from this investigation for all three 
groups. Yellow boxes indicate beams which came from the medial position and green 
boxes indicate beams which came from the lateral position. 
 
Table F1. Control Data 
Beam 
Number 
Stress 
(MPa) 
Nf 
(Cycles) 
Secant Ei 
(GPa) 
Secant Ef 
(GPa) 
Secant Loss 
(GPa) 
Secant Loss 
(%) 
59210_A 45 35000 8.73 5.33 3.40 38.90 
60628_A 52 14000 7.89 4.72 3.18 40.22 
59315_C 52 3000 6.43 4.86 1.57 24.41 
60634_A 52 1000 8.14 5.23 2.91 35.74 
60644_A 60 298 6.70 2.30 4.39 65.60 
60632_E 60 5000 9.91 4.69 5.22 52.68 
59315_A 67 70 6.16 4.42 1.74 28.21 
59234_B 67 28 4.35 3.63 0.71 16.44 
60632_A 75 1200 7.62 2.97 4.65 61.05 
60628_C 75 56 6.19 4.00 2.19 35.39 
60632_C 85 414 7.54 2.92 4.62 61.24 
59677_D 85 60 6.80 3.78 3.02 44.38 
Average 
  
7.21 4.07 3.13 42.02 
STDEV 
  
1.43 0.97 1.41 15.54 
 
Table F2. Aln 0.2 Data 
Beam 
Number 
Stress 
(MPa) 
Nf 
(Cycles) 
Secant Ei 
(GPa) 
Secant Ef 
(GPa) 
Secant Loss 
(GPa) 
Secant 
Loss 
(%) 
60631_C 45 740 6.59 4.88 1.71 25.90 
59256_E 45 20000 7.36 3.50 3.86 52.46 
60642_A 52 250 6.70 4.11 2.59 38.62 
60592_E 52 3000 7.93 4.47 3.46 43.59 
59258_C 55 19052 7.40 3.91 3.48 47.08 
59219_C 67 204 6.90 2.80 4.09 59.34 
60592_A 67 95 6.99 2.65 4.34 62.12 
60642_F 75 57 5.28 3.65 1.62 30.72 
59219_A 75 600 7.84 4.60 3.24 41.31 
Average 
  
7.00 3.84 3.15 44.57 
STDEV 
  
0.80 0.77 0.98 12.15 
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Table F3. Aln 1.0 Data 
Beam 
Number 
Stress 
(MPa) 
Nf 
(Cycles) 
Secant Ei 
(GPa) 
Secant Ef 
(GPa) 
Secant Loss 
(GPa) 
Secant Loss 
(%) 
60657_C 45 2000 6.32 4.58 1.75 27.59 
60750_G 52 5000 7.10 4.67 2.43 34.19 
59236_B 60 463 6.61 3.65 2.96 44.75 
59236_C 75 349 5.76 4.19 1.57 27.28 
59231_B 75 81 5.67 4.00 1.68 29.53 
59211_C 75 86 5.56 2.76 2.80 50.41 
59236_A 85 258 5.35 - - - 
60641_D 85 39 5.69 3.80 1.88 33.10 
59211_E 85 29 4.36 3.62 0.75 17.12 
60643_E 85 256 7.21 2.57 4.64 64.33 
Average 
  
5.96 3.76 2.27 36.48 
STDEV 
  
0.86 0.72 1.12 14.32 
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APPENDIX G 
STIFFNESS DATA BY LOCATION 
The following tables contain stiffness data from both medial (med) and lateral 
(lat) positions. Yellow boxes indicate beams which came from the medial position and 
green boxes indicate beams which came from the lateral position 
 
Table G1. Control Data 
Stress 
Amplitude 
Secant Ei 
(GPa) 
Secant Ef 
(GPa) 
Secant Loss 
(GPa) 
Secant Loss 
(%) 
 Lat Med Lat Med Lat Med Lat Med 
45 8.73 10.09 5.33 7.78 3.40 2.31 38.90 23.65 
52 8.70 12.46 5.39 9.45 3.31 3.01 36.40 24.70 
60 8.30 9.94 3.50 4.60 4.81 5.34 59.14 52.83 
67 5.25 11.06 4.03 5.41 1.23 5.65 22.33 51.11 
75 6.91 11.30 3.49 5.74 3.42 5.56 48.22 49.19 
85 7.17 11.06 3.35 5.38 3.82 5.68 52.81 50.96 
Average 7.51 10.99 4.18 6.39 3.33 4.59 42.97 42.08 
STDEV 1.35 0.91 0.94 1.84 1.17 1.52 13.20 13.92 
 
Table G2.  Aln 0.2 Data 
Stress 
Amplitude 
Secant Ei 
(GPa) 
Secant Ef 
(GPa) 
Secant Loss 
(GPa) 
Secant Loss 
(%) 
 Lat Med Lat Med Lat Med Lat Med 
45 8.80 10.32 4.87 5.90 5.14 5.90 40.93 42.48 
50 11.26 - 4.91 - 6.34 - 56.35 - 
52 8.24 8.76 4.43 5.17 3.81 5.17 45.19 40.68 
55 7.40 10.45 3.91 6.64 3.48 6.64 47.08 63.57 
60 9.34 11.50 5.57 4.60 3.76 4.60 40.19 59.74 
67 7.86 12.45 2.62 6.00 5.24 6.00 66.02 51.87 
75 7.32 11.57 4.65 5.92 2.67 5.92 35.93 48.40 
85 10.30 9.16 4.73 3.66 5.58 3.66 56.07 59.52 
Average 8.81 10.60 4.46 5.41 4.50 5.59 48.47 52.32 
STDEV 1.41 1.34 0.88 1.01 1.25 1.22 10.16 8.96 
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Table G.3   Aln 1.0 Data 
Stress 
Amplitude 
Secant Ei 
(GPa) 
Secant Ef 
(GPa) 
Secant Loss 
(GPa) 
Secant Loss 
(%) 
 Lat Med Lat Med Lat Med Lat Med 
45 7.54 - 4.30 - 3.24 - 42.40 - 
52 7.92 9.96 4.38 4.91 3.54 5.05 43.72 51.13 
60 7.53 9.39 3.33 4.94 4.20 4.45 55.01 47.84 
67 6.39 9.06 3.62 3.86 2.77 5.20 41.48 58.01 
75 6.13 8.71 3.23 3.52 3.10 5.19 44.56 57.88 
85 7.54 7.57 4.30 3.03 3.24 4.55 42.40 60.06 
Average 7.10 8.94 3.77 4.05 3.37 4.89 45.44 54.98 
STDEV 0.79 0.89 0.54 0.85 0.54 0.36 5.48 5.23 
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APPENDIX H 
POROSITY DATA 
The following tables contain the porosity data using in this investigation. 
 
Table H1. Control Data 
Beam 
Number 
Beam 
Area 
(mm
2
) 
Total 
Porosity 
(mm
2
) 
Porosity 
(%) 
Number 
of Pores 
(#) 
Average Pore 
Size 
(mm
2
) 
Pore 
Density 
(#/mm
2
) 
60632_D 0.65 0.010 1.59 33.67 0.00031 51.67 
60628_B 0.61 0.013 2.14 32.00 0.00041 52.05 
60628_D 0.70 0.016 2.27 33.33 0.00048 47.51 
59315_B 0.73 0.013 1.75 34.00 0.00038 46.39 
59234_A 0.57 0.017 2.94 27.50 0.00061 48.01 
59234_C 0.51 0.006 1.18 24.00 0.00025 47.01 
59315_D 0.75 0.015 2.03 37.33 0.00041 49.72 
60667_A 0.63 0.013 2.10 35.20 0.00038 55.47 
60628_F 0.71 0.017 2.37 33.33 0.00050 47.22 
Average 0.65 0.013 2.04 32.26 0.00041 49.45 
STDEV 0.079 0.0035 0.50 4.07 0.00011 3.04 
 
Table H2. Aln 0.2 Data 
Beam 
Number 
Beam 
Area 
(mm
2
) 
Total 
Porosity 
(mm
2
) 
Porosity 
(%) 
Number 
of Pores 
(#) 
Average Pore 
Size 
(mm
2
) 
Pore 
Density 
(#/mm
2
) 
59258_D 0.87 0.018 2.02 50.75 0.00035 58.26 
60636_F 0.79 0.025 3.20 54.67 0.00047 68.86 
59219_B 0.85 0.022 2.61 38.00 0.00058 44.90 
59219_F 0.78 0.010 1.29 24.67 0.00041 31.77 
60592_D 0.82 0.017 2.11 42.00 0.00041 51.03 
59256_F 0.67 0.022 3.21 23.00 0.00094 34.35 
59258_E 0.72 0.019 2.67 37.40 0.00052 51.68 
60636_A 0.74 0.018 2.39 40.25 0.00044 54.48 
60636_C 0.61 0.014 2.36 28.33 0.00051 46.42 
60636_E 0.86 0.022 2.51 46.50 0.00047 53.99 
60642_E 0.72 0.014 1.92 36.20 0.00038 50.03 
60631_E 0.69 0.015 2.21 36.60 0.00041 53.40 
59256_A 0.76 0.016 2.09 32.80 0.00048 43.18 
59256_C 0.65 0.017 2.58 34.00 0.00050 51.99 
Average 0.75 0.018 2.37 37.51 0.00049 49.59 
STDEV 0.081 0.0040 0.50 9.09 0.00014 9.36 
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Table H3. Aln 1.0 Data 
Beam 
Number 
Beam 
Area 
(mm
2
) 
Total 
Porosity 
(mm
2
) 
Porosity 
(%) 
Number 
of Pores 
(#) 
Average 
Pore Size 
(mm
2
) 
Pore 
Density 
(#/mm
2
) 
59231_A 0.49 0.0104 2.13 29.00 0.00036 59.235 
59231_D 0.98 0.0246 2.50 67.00 0.00037 68.113 
60641_B 0.78 0.0204 2.62 48.33 0.00042 62.227 
59236_D 0.82 0.0153 1.88 48.00 0.00032 58.891 
60643_A 0.64 0.0135 2.12 22.67 0.00060 35.555 
60657_D 0.69 0.0177 2.58 38.50 0.00046 56.113 
60641_C 0.62 0.0081 1.31 27.50 0.00029 44.588 
59211_A 0.45 0.0084 1.85 24.00 0.00035 53.043 
60750_E 0.61 0.0096 1.58 24.00 0.00040 39.443 
59238_A 0.74 0.0204 2.76 36.50 0.00056 49.310 
59231_E 0.72 0.0163 2.26 39.75 0.00041 55.314 
60809_A 0.71 0.0298 4.22 28.50 0.00105 40.405 
Average 0.69 0.0162 2.32 36.15 0.00046 51.853 
STDEV 0.14 0.0068 0.74 13.21 0.00020 10.079 
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APPENDIX I 
OSTEONAL AND INTEROSTEONAL DATA 
The following tables contain the osteonal and interosteonal data using in this 
investigation. 
 
Table I1. Control Data 
Beam 
Number 
Osteonal 
Area 
(mm
2
) 
Osteonal 
Area 
(%) 
Average 
Osteon size 
(mm
2
) 
Interosteonal 
Space 
 (%) 
60632_D 0.35 53.37 0.010 45.04 
60628_B 0.30 49.59 0.010 48.27 
60628_D 0.43 61.81 0.013 35.93 
59315_B 0.50 68.44 0.015 29.81 
59234_A 0.29 51.22 0.011 45.84 
59234_C 0.30 58.60 0.012 40.23 
59315_D 0.49 64.70 0.013 33.27 
60667_A 0.41 64.17 0.012 33.73 
60628_F 0.35 49.32 0.010 48.31 
Average 0.38 57.91 0.012 40.05 
STDEV 0.08 7.25 0.002 7.09 
 
Table I2. Aln 0.2 Data 
Beam 
Number 
Osteonal 
Area 
(mm
2
) 
Osteonal 
Area 
(%) 
Average 
Osteon size 
(mm
2
) 
Interosteonal 
Space 
 (%) 
59258_D 0.51 58.34 0.010 39.64 
60636_F 0.47 59.49 0.009 37.30 
59219_B 0.48 56.56 0.013 40.83 
59219_F 0.19 24.93 0.008 73.78 
60592_D 0.51 62.03 0.012 35.86 
59256_F 0.36 53.33 0.016 43.45 
59258_E 0.42 58.39 0.011 38.94 
60636_A 0.41 56.07 0.010 41.54 
60636_C 0.27 44.33 0.010 53.31 
60636_E 0.38 43.68 0.008 53.81 
60642_E 0.42 57.51 0.011 40.57 
60631_E 0.43 62.85 0.012 34.94 
59256_A 0.43 56.80 0.013 41.11 
59256_C 0.34 51.97 0.010 45.45 
Average 0.40 53.31 0.011 44.32 
STDEV 0.089 9.94 0.0021 10.17 
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Table I3. Aln 1.0 Data 
Beam 
Number 
Osteonal 
Area 
(mm
2
) 
Osteonal 
Area 
(%) 
Average 
Osteon size 
(mm
2
) 
Interosteonal 
Space 
(%) 
59231_A 0.28 56.92 0.0096 40.95 
59231_D 0.57 57.55 0.0084 39.94 
60641_B 0.42 54.54 0.0088 42.84 
59236_D 0.47 57.39 0.0097 39.30 
60643_A 0.32 49.77 0.0140 48.11 
60657_D 0.31 45.13 0.0080 52.30 
60641_C 0.26 42.13 0.0094 56.57 
59211_A 0.23 50.68 0.0096 47.47 
60750_E 0.23 37.28 0.0095 61.14 
59238_A 0.34 45.87 0.0093 51.37 
59231_E 0.38 52.47 0.0095 45.27 
60809_A 0.31 44.61 0.0110 51.17 
Average 0.34 49.53 0.0097 48.03 
STDEV 0.10 6.59 0.0015 6.81 
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APPENDIX J 
CREEP DATA 
The following tables contain strain (ε) data for elastic, e, (recovered) and plastic, p, 
(accumulated) deformation at initial (o) and final (n) cycles.  
 
Table J1. Control Data 
Beam 
Number εp, o εe, o εp, n εe, n 
Creep 
εp, o / εp, n 
Secant 
εe, o  / εe, n 
59315_D 0.0033 0.0062 0.0262 0.0134 0.1265 0.4606 
59677_C 0.0046 0.0080 0.0352 0.0235 0.1310 0.3414 
60628_E 0.0054 0.0089 0.0825 0.0288 0.0660 0.3095 
60628_F 0.0032 0.0057 0.0337 0.0154 0.0959 0.3667 
60632_F 0.0053 0.0089 0.0435 0.0246 0.1207 0.3628 
60644_H 0.0064 0.0107 0.0387 0.0320 0.1651 0.3349 
60667_A 0.0028 0.0051 0.0109 0.0094 0.2545 0.5455 
60707_B 0.0041 0.0072 0.0292 0.0259 0.1412 0.2760 
59257_D 0.0054 0.0092 0.0349 0.0277 0.1560 0.3333 
60632_B 0.0564 0.0099 0.0895 0.0394 0.6305 0.2504 
60632_D 0.0020 0.0117 0.0322 0.0240 0.0629 0.4875 
60628_B 0.0024 0.0161 0.0457 0.1275 0.0520 0.1263 
60628_D 0.0021 0.0115 0.0723 0.0304 0.0285 0.3768 
59315_B 0.0015 0.0071 0.0104 0.0092 0.1457 0.7687 
59234_A 0.0590 0.0079 0.0872 0.0157 0.6771 0.5046 
59234_C 0.0023 0.0117 0.0267 0.0218 0.0864 0.5394 
Average 0.010 0.009 0.044 0.029 0.184 0.399 
STDEV 0.019 0.003 0.025 0.027 0.191 0.149 
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Table J2. Aln 0.2Data 
Beam 
Number εp, o εe, o εp, n εe, n 
Creep 
εp, o / εp, n 
Secant 
εe, o  / εe, n 
59219_B 0.0002 0.0233 0.059 0.038 0.003 0.613 
59219_F 0.0002 0.0156 0.023 0.024 0.007 0.655 
60592_B 0.0044 0.0073 0.036 0.020 0.122 0.367 
60592_D 0.0043 0.0076 0.039 0.023 0.108 0.337 
60592_F 0.0057 0.0075 0.033 0.020 0.174 0.369 
60636_A 0.0037 0.0061 0.069 0.020 0.053 0.303 
60636_C 0.0050 0.0074 0.051 0.021 0.099 0.353 
60636_E 0.0041 0.0070 0.062 0.061 0.066 0.115 
60636_F 0.0030 0.0059 0.030 0.024 0.101 0.245 
59256_A 0.0031 0.0139 0.091 0.050 0.034 0.280 
59256_C 0.0036 0.0141 0.037 0.026 0.100 0.533 
59256_F 0.0035 0.0059 0.029 0.013 0.123 0.455 
59256_G 0.0081 0.0095 0.086 0.052 0.094 0.184 
60631_B 0.0088 0.0116 0.067 0.059 0.131 0.197 
60631_D 0.0003 0.0105 0.034 0.019 0.010 0.542 
60631_E 0.0104 0.0126 0.075 0.057 0.138 0.222 
60631_F 0.0050 0.0082 0.052 0.026 0.095 0.315 
60631_G 0.0002 0.0140 0.035 0.022 0.006 0.625 
60631_H 0.0047 0.0078 0.045 0.026 0.104 0.302 
60642_E 0.0061 0.0097 0.041 0.025 0.150 0.382 
59258_B 0.0039 0.0072 0.023 0.031 0.167 0.234 
59258_D 0.0024 0.0095 0.024 0.017 0.101 0.569 
59258_E 0.1401 0.2108 0.032 0.014 4.344 14.635 
Average 0.010 0.019 0.047 0.030 0.275 0.993 
STDEV 0.028 0.042 0.020 0.015 0.888 2.978 
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Table J3. Aln 1.0 Data 
Beam 
Number εp, o εe, o εp, n εe, n 
Creep 
εp, o / εp, n 
Secant 
εe, o  / εe, n 
59231_E 0.0095 0.0136 0.0680 0.0548 0.1392 0.2482 
59236_D 0.0062 0.0092 0.0395 0.0295 0.1574 0.3134 
59238_A 0.0054 0.0072 0.0672 0.0238 0.0808 0.3023 
59238_B 0.0044 0.0066 0.0317 0.0166 0.1404 0.3991 
60593_A 0.0036 0.0061 0.0365 0.0220 0.0995 0.2771 
60643_A 0.0090 0.0098 0.0728 0.0495 0.1242 0.1978 
60643_C 0.0098 0.0108 0.0798 0.0393 0.1227 0.2742 
60643_D 0.0065 0.0105 0.0658 0.0464 0.0995 0.2271 
60750_D 0.0098 0.0135 0.0574 0.0383 0.1713 0.3531 
60809_A 0.0083 0.0098 0.1163 0.0334 0.0716 0.2921 
60750_E 0.0059 0.0073 0.0372 0.0217 0.1578 0.3350 
59231_A 0.0576 0.0093 0.1247 0.0258 0.4617 0.3600 
59231_C 0.0019 0.0129 0.0407 0.0297 0.0460 0.4331 
59231_D 0.0017 0.0112 0.2710 0.0023 0.0063 4.8261 
60641_B 0.0025 0.0092 0.0371 0.0237 0.0687 0.3892 
59211_B 0.0023 0.0132 0.0484 0.0293 0.0477 0.4507 
59211_D 0.0017 0.0076 0.0055 0.0080 0.3088 0.9495 
60593_B 0.0084 0.0135 0.0523 0.0466 0.1607 0.2884 
60657_D 0.0598 0.0171 0.1126 0.0347 0.5311 0.4920 
60641_C 0.0032 0.0088 0.0317 0.0182 0.0996 0.4858 
59211_A 0.0028 0.0135 0.0806 0.0436 0.0347 0.3086 
Average 0.0105 0.0105 0.0703 0.0303 0.1490 0.5811 
STDEV 0.0163 0.0029 0.0551 0.0136 0.1324 0.9850 
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Table J4. Control Outliers 
Beam 
Number εp, o εe, o εp, n εe, n 
Creep 
εp, o / εp, n 
Secant 
εe, o  / εe, n 
59210_A 0.005 0.006 0.041 0.017 0.122 0.381 
59677_D 0.017 0.016 0.085 0.035 0.200 0.474 
60632_E 0.005 0.009 0.044 0.026 0.118 0.337 
60634_A 0.006 0.008 0.031 0.020 0.197 0.380 
60644_A 0.010 0.011 0.095 0.050 0.104 0.226 
60632_A 0.058 0.017 0.142 0.050 0.408 0.337 
60632_C 0.057 0.019 0.027 0.211 2.105 0.090 
60628_A 0.061 0.011 0.104 0.022 0.588 0.512 
60628_C 0.006 0.018 0.061 0.033 0.100 0.530 
59315_A 0.063 0.018 0.098 0.030 0.645 0.610 
59315_C 0.004 0.014 0.042 0.021 0.092 0.644 
59234_B 0.010 0.021 0.114 0.050 0.085 0.426 
Average 0.025 0.014 0.074 0.047 0.397 0.412 
STDEV 0.026 0.005 0.038 0.053 0.573 0.157 
 
 
Table J5. Aln 0.2 Outliers 
Beam 
Number εp, o εe, o εp, n εe, n 
Creep 
εp, o / εp, n 
Secant 
εe, o  / εe, n 
59219_A 0.0083 0.0112 0.0423 0.0293 0.1950 0.3811 
59219_C 0.0104 0.0106 0.0716 0.0426 0.1457 0.2479 
60592_A 0.0123 0.0107 0.0666 0.0454 0.1853 0.2358 
60592_E 0.0059 0.0087 0.0360 0.0232 0.1627 0.3758 
59256_E 0.0031 0.0104 0.1052 0.0068 0.0294 1.5325 
60631_C 0.0092 0.0079 0.0221 0.0183 0.4181 0.4311 
60642_A 0.0076 0.0093 0.0474 0.0249 0.1611 0.3728 
60642_F 0.0175 0.0182 0.0938 0.0330 0.1864 0.5508 
59258_C 0.0077 0.0101 0.0844 0.0334 0.0912 0.3018 
Average 0.0091 0.0108 0.0633 0.0286 0.1750 0.4922 
STDEV 0.0041 0.0030 0.0282 0.0120 0.1056 0.4017 
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Table J6. Aln 1.0 Outliers 
Beam 
Number εp, o εe, o εp, n εe, n 
Creep 
εp, o / εp, n 
Secant 
εe, o  / εe, n 
60643_E 0.0123 0.0157 0.0960 0.0644 0.1286 0.2438 
60750_G 0.0074 0.0086 0.0600 0.0104 0.1230 0.8333 
59236_B 0.0330 0.0139 0.0764 0.0339 0.4320 0.4112 
59236_C 0.0428 0.0172 0.1119 0.0272 0.3822 0.6323 
60657_C 0.0609 0.0125 0.0874 0.0197 0.6964 0.6381 
59231_B 0.0046 0.0228 0.0707 0.0386 0.0644 0.5903 
60641_D 0.0042 0.0276 0.0531 0.0370 0.0801 0.7471 
59211_C 0.0038 0.0263 0.0801 0.0533 0.0468 0.4923 
59211_E 0.0035 0.0373 0.0763 0.0382 0.0456 0.9767 
Average 0.0192 0.0202 0.0791 0.0359 0.2221 0.6183 
STDEV 0.0212 0.0090 0.0179 0.0163 0.2292 0.2213 
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